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ABSTRACT 
 Peptide and protein therapeutics encounter proteases at every stage of delivery, beginning 
at the site of administration and ending in the intracellular lysosomal compartment. An intact, 
stable molecule is desired upon administration, yet release of the payload or activation of the 
prodrug is necessary at the target site. Successful payload release or prodrug activation can be 
accomplished using enzymatic recognition sequences specific to proteases expressed in the 
tumor environment or within endocytic vesicles of the target cell. Control of the proteolytic 
susceptibility of biologics is essential to deliver a safe and effective molecule. Although 
degradation and release of proteins is desired at the target site, stability in the systemic 
circulation is required for successful delivery. Proteins and peptides often succumb to proteolysis 
in the systemic circulation, causing short half-lives due to their small size resulting in rapid 
filtration by the kidney. Proteases in the systemic circulation reduce half-life further through 
fragmentation rendering the biologic inactive. Achieving stability in the systemic circulation 
would greatly improve the half-life and efficacy of delivered biologics.  
 Considering the half-life of peptides and proteins is especially important when they are 
used as diagnostic imaging agents. Contrast agents need a sufficient amount of time to 
accumulate at the target site to generate a high-quality image. Current contrast agents or 
diagnostic tracers consist of large chelators bound to lanthanide metals and are chemically 
conjugated to proteins creating a heterogeneous, unstable and toxic molecule. A common 
lanthanide ion used for imaging applications is gadolinium, which is often released from the 
chelator upon dilution into the body and accumulates in the kidney, causing renal toxicity. An 
improvement to chemically conjugated diagnostic imaging agents is to use a metal-binding 
tripeptide known as the claMP Tag. The claMP Tag consists of the amino acid sequence Asn-
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Cys-Cys and binds transition metals tightly at basic pH. Biocompatible transition metals such as 
copper and cobalt can be used to create a safe and effective molecular imaging agent. The claMP 
Tag enables design of a site-specific, homogenous and safe molecule, none of which is possible 
using current lanthanide binding tags.  
 The compatibility of the claMP Tag within a metalloproteinase was investigated. Herein 
is the first application where the claMP Tag was placed within a molecule with a structural or 
catalytic metal-binding site. One hypothesis was that the claMP Tag would be able to interact 
with the catalytic Zn active site inhibiting the protease, while release of the claMP Tag could 
activate the enzyme. The claMP Tag followed by an eight-amino acid linker was engineered to 
the N-terminus of matrix metalloproteinase-8 (MMP-8). MMP-8 is very difficult to produce 
because of its inherent function of degrading extra cellular matrix (ECM) proteins and 
concomitant autoproteolysis. Production of this enzyme proved difficult as several fusion 
constructs were created and determined to be unsuccessful. A fusion construct consisting of a 
thioredoxin and S Tag, as well as, a polyhistidine tag enabled expression and purification of 
active, soluble MMP-8 in high yield. Studies were completed both with and without the claMP 
Tag placed inline with MMP-8. The claMP Tag had no structural or functional implications on 
the production of MMP-8. Further investigation of the claMP Tag as a modulator of enzymatic 
activity is of interest. 
 Another focus of this work was to investigate the proteolytic stability of claMP-Tagged 
proteins. To investigate the proteolytic susceptibility of a protein containing the claMP Tag, a 
proof of concept study was designed to investigate the ability of the claMP Tag to inhibit 
adjacent proteolysis by a serum protease. The stability of the metal-bound and apo claMP Tag 
were compared to determine the effect of metal-binding on proteolysis. The claMP Tag inhibits 
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proteolysis 3-fold compared to the control and use of the claMP Tag in applications creates a 
more proteolytically stable molecule. Following the proof of concept study, a targeted imaging 
agent was designed using the claMP Tag and the proteolytic stability of this molecule was 
analyzed. Previously, the claMP Tag was placed inline with the targeting protein, epidermal 
growth factor (EGF), and the structure and function of the protein were determined to be 
unaltered. EGF is a small protein that binds to the receptor EGFR and can be used to target 
EGFR (+) tumor cells, making EGF ideal for diagnostic imaging. One limitation is EGF has a 
very short half-life of only 3-7 min. Thus, to improve the half-life, addition of a polymer of 
amino acids, known as XTEN, was engineered to the C-terminus of EGF. Three EGF-claMP-
XTEN molecules were created and analyzed for the structural and functional implications of the 
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CHAPTER 1. ASSESSMENT OF THE PROTEOLYTIC STABILITY OF BIOLOGICS 
IN VIVO 
1.1 INTRODUCTION 
 Although biologics are naturally derived, well-tolerated and present many advantages 
such as low toxicity compared to small molecules, the proteolytic stability of biologics limits 
their potential use as therapeutic and diagnostic agents.1 Metabolism and degradation of 
biologics (i.e., proteins, peptides, oligonucleotides) are rapid in the body because they are 
naturally derived molecules. Mechanisms of proteolytic degradation of biologics cause short 
half-lives, resulting in their rapid excretion. Proteolytic enzymes are encountered at every site 
and step of drug delivery, including the initial site of administration, within the systemic 
circulation, in tissue matrices, and intracellularly within lysosomes. A balance between stability 
in the systemic circulation and degradation at the target site is necessary to achieve effective 
targeted delivery. For example, protease-activated prodrugs consist of the active parent drug with 
an additional prodomain or promoiety that, upon proteolytic cleavage of the promoiety, generates 
the active form of the parent drug.2,3 Release of the active drug is desired to occur at the site of 
interest, yet stability must be retained during transport to the site of action. For example, 
antibody-drug conjugates (ADCs) are intended to be stable in the systemic circulation and then 
degraded to release the drug toxin in the intracellular lysosome of the target cell. Strategies to 
control metabolic degradation have been utilized to improve the performance of biologics and to 
create next-generation products with more desirable clinical characteristics. 
 Proteases are intricate and multi-functional molecules, which makes it difficult to predict 
their site of action and level of activity toward a specific biologic.4 The human degradome is 
located in both intra- and extracellular spaces and it consists of 569 proteases that are classified 
into five types: cysteine, serine, threonine, aspartic, and metalloproteinases.5,6 Proteolysis of a 
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biologic substrate is dictated by the accessibility or proximity of the enzyme to the substrate and 
its cleavage site(s). Substrate selection among proteases is diverse and some proteases are highly 
specific and cleave only at a particular recognition sequence while others cleave following a 
specific amino acid or multiple amino acids. For example, Factor Xa cleaves after arginine at the 
C-terminus of its recognition sequence (i.e., Ile-(Glu-Asp)-Gly-Arg) with relatively high fidelity, 
whereas trypsin cleaves at the C-terminal of the lysine or arginine residues with little sequence 
specificity. Predicting the specificity and activity of each protease in vivo is extremely difficult, 
but is of interest to understand the functional role of proteolytic events in biological processes. 
One way to identify proteolysis events is to label the N-terminal amine of the substrate. Any 
proteolysis at the cleavage site that occurs on the labeled substrate can be identified using LC-
MS/MS.7 This method can be used to determine proteolytic cleavage of the substrate biologic at 
a specific site(s) within the body, for example in the blood, liver, intestines, or kidney. This 
enables the design of biologics with higher stability.8-10  
 This chapter focuses on the role of proteolytic enzymes in designing proteins and 
peptides as therapeutic and diagnostic agents. Deciphering proteolytic activity and specificity 
that produces unwanted degradation in biologic products can be utilized to improve the design 
and/or formulation of biologics. Identifying protease cleavage sequences and structural 
preferences will help in the design of the next generation of proteins or peptides with improved 
stability at the site of administration and in the systemic circulation. 
1.2 FACTORS THAT INFLUENCE PROTEOLYSIS 
1.2.1 Effects of Individual Chemical Moieties  
 Recognition of the substrate by a protease is determined by hydrogen bonding and 
hydrophobic (non-polar) interactions at multiple sites on the substrate and the enzyme active 
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site.11 Proteases typically prefer cleavage at the amide bond between two amino acid residues, 
caused by specific recognition of the two or more amino acid backbones and side chains of the 
substrate cleavage site by the enzyme binding pocket or active site. Mutation of the amino acid 
on the substrate cleavage site can greatly decrease or abolish the proteolytic degradation of the 
substrate. Because the body is teeming with proteases, peptide and protein therapeutics often 
display poor efficacy because of rapid fragmentation and clearance from the body, resulting in a 
very short half-life. Often, enzymatic degradation inactivates a therapeutic protein; this can be 
due to degradation of an active site of the drug. For example, glucagon-like peptide 1 (GLP-1), a 
30-amino acid peptide hormone that regulates glucose levels through release of insulin, has a 
circulation half-life of only 3 min upon intravenous (I.V.) administration.12 Prior to rapid kidney 
filtration, GLP-1 is inactivated by the dipeptidyl peptidase IV (DPP-IV) enzyme, which removes 
the first two N-terminal amino acids, decreasing the half-life to 1–2 min.13 DPP-IV specifically 
cleaves peptides from the glucagon family after the second N-terminal amino acid, in this case, 
the alanine residue. Removal of the two N-terminal amino acids decreases the binding affinity to 
the GLP-1 receptor 100-fold, rendering the peptide inactive.14 A second protease, neutral 
endopeptidase 24.11 (NEP 24.11), cleaves at multiple sites of GLP-1, including between Ala15-
Val16, Ser18-Tyr19, Tyr19-Leu20, Glu27-Phe28, Phe28-Ile29, and Trp31-Leu32, causing 
complete degradation.15,16 A mutation of the second amino acid, Ala to Gly, inhibits proteolysis 
by DPP-IV, extending the half-life to 60–90 min.17,18 Therefore, when a site of proteolysis is 
known, mutation of a specific amino acid can greatly improve half-life; however, inhibiting a 
broad range of proteases at multiple susceptible sites requires alternative approaches.  
 To inhibit a broad range of proteases, six common modifications of the peptide backbone 
can be implemented, including: (1) incorporation of a N-methylated amide bond, (2) mutation of 
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an L- to D-amino acid residue, (3) C-methylation of the a-carbon of the amino acid (e.g., a-
aminoisobutyric acid, Aib), (4) mutation with b2 residues, and (5) mutation with b3 residues 
(Figure 1.1).19,20 First, methylation of the peptide backbone is a common modification used to 
suppress proteolysis without losing the biological activity of the peptide. For example, three sites 
of somatostatin were N-methylated to produce octreotide with a 5-fold increase in half-life.21 
Second, a substitution from the natural L-amino acid to a D-amino acid within the cleavage site 
can improve the enzymatic stability of peptides because proteases cleave only natural L-amino 
acids. For example, the proteolytic stability of an 11-amino acid peptide used to prevent 
aggregation of amyloid-b (Ab) peptides was improved using D-amino acid mutations. The 
mutated peptide was stable when incubated with high protease concentrations for extended 
periods of time.22 Third, a-aminoisobutyric acid (Aib) is an unnatural amino acid that binds to 
the cell membrane. Aib is present in the peptaibol family of peptide antibiotics, and the presence 
of Aib in the peptide suppresses their degradation by trypsin. Further, strategic placement of Aib 
residues in a peptide completely abolished enzymatic degradation.23 Lastly, b-amino acids have 
an extended methylene group, either between the amino and a carbon (b2) or between the 
carboxylate and a carbon (b3).20 Addition of b-amino acids in several peptide substrates has been 
shown to eliminate peptide proteolytic degradation.24 Because b-amino acid-substituted peptides 
have the propensity to form helical, turn, or extended structures, it is necessary to ensure that 
	
Figure 1.1 Inhibition of proteolysis across a broad range of proteolytic sites can be accomplished using 
chemical mutations. The structure of five of the commonly used non-natural residues are compared to the 
natural a-amino acid on the far left.  
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mutated peptides retain their biological activity.25 It should be noted that any addition of 
chemically altered amino acids can influence the target selectivity and bioactivity of the 
modified peptide. Thus, it is necessary to continuously reevaluate the peptide activity and 
stability during the peptide modification process.26,27 The peptide backbone modifications were 
made to a designed peptide and proteolysis at a specific cleavage site was analyzed for each of 
the backbone modifications. Comparison of the proteolytic susceptibility of the peptide backbone 
modification determined D-amino acids were the most effective modification and it could 
increase peptide half-life from 100 to 1000-fold.19 In contrast, modification with N-methylation 
of the peptide bond was the least effective in increasing peptide enzymatic stability.  
1.2.2 Effects of Secondary Structure 
 Proteases normally cleave flexible and unstructured regions of proteins much more 
rapidly than the rigid and structured regions. For example, a region with a-helical structure is 
proteolytically more stable than the b-sheet region. Analysis of multiple crystal structures 
showed that the enzyme active site binds to extended b-strand regions of the ligand.28 Thus, 
imposing a-helical structure at the cleavage site of a peptide or protein can potentially decrease 
proteolytic degradation. Typically, small peptides have a low propensity to form a-helix 
structure; thus, the a-helical structure can be induced and stabilized using a hydrocarbon staple 
or a disulfide bond within the helical residues (Figure 1.2). A disulfide bond or staple formation 
between two a-helices can improve the stability of peptides 1000-fold (Figure 1.2 A).29 One 
disadvantage of using a disulfide bond is that it can be dissociated in vivo by reducing agents 
(e.g., glutathione) in tissues; thus, a hydrocarbon staple is a more stable crosslink than a disulfide 
bond. To generate a hydrocarbon staple, two unnatural amino acids containing an alkyne arm are 
integrated into the peptide sequence. Then, the olefin metathesis reaction is carried out to link the 
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two alkyne groups and to create a staple across one or two turns in an a-helix (Figure 1.2 B).30 It 
has been shown that a peptide with a staple was 41-fold more stable than the parent non-stapled 
peptide.30 A natural hydrogen bond can be strategically replaced with hydrogen bond surrogates 
(HBS) to induce and stabilize an a-helix structure within a peptide (Figure 1.2 C).31 An 
unconstrained peptide that binds Bcl-xL and regulates cell death was modified using HBS to 
create a peptide analog (Bak); Bak peptide has a 30-fold slower degradation rate compared to the 
unconstrained parent peptide.32 Cyclic peptides have previously been shown to have higher 
stability toward proteolysis than do their parent linear peptides. This is due to a more rigid 
backbone of the cyclic peptide, which does not allow the optimal binding to the active site of the 
proteolytic enzyme. As an example, a natural cyclic peptide, kahalalide F, is resistant to 
proteases in plasma.33 In summary, these modifications may be incorporated into a peptide 
whenever possible to improve the enzymatic stability of the peptide without sacrificing the 
biological activity. 
	
Figure 1.2 Implementation of a-helical structure improves stability against proteolytic cleavage. Three 
methods of employing covalent bonds to stabilize a-helical structure are: (A) disulfide bond staples, (B) 
hydrocarbon cross-links, and (C) hydrogen bond surrogates.29-31  
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1.2.3 Inaccessibility to Proteases  
 Polymers are often added to peptides and proteins to increase in vivo circulating half-life 
by avoiding glomerular filtration (Table 1.1). Not only is glomerular filtration prevented, access 
to proteolytic sites can be inhibited via steric hindrance in the presence of a polymer. 
Polyethylene glycol (PEG) is a synthetic, hydrophilic polymer that has been conjugated to 
peptides and proteins to increase the solubility and hydrodynamic radius of the molecules 
because every ethylene oxide unit can coordinate 2–3 water molecules.34 For example, PEG was 
conjugated to the N-terminus of a recombinant methionyl human granulocyte colony-stimulating 
factor (Pegfilgrastim or Neulasta®) that is used to treat patients with low white blood cell count 
(neutropenia) after chemotherapy treatments. Pegfilgrastim can be administered less often than 
the parent protein, and this improves patient compliance.35 Pegfilgrastim decreased clearance by 
8.6-fold compared to filgrastim, enabling administration once every 21 days rather than daily.36 
Strategic conjugation of PEG to a site(s) on the peptide or protein is important to consider 
for maintaining peptide activity while preventing proteolysis. Investigating optimal PEGylation 
site(s) on human Pin 1 WW domain protein resulted in improved proteolytic and conformational 
stability.37 The PEGylated protein has a 1.7- to 3.6-fold increase in half-life compared to the 
parent protein upon exposure to pronase and proteinase k, respectively.37 PEGyation at a site that 
is important for biological activity can reduce protein activity; for example, PEGylation at a 
native Cys or Lys residue in interferon alpha-2b (IFN a-2b) (PegIntron®) caused a loss of  92% 
or 93% of the cytokine activity, respectively. However, PEGylation increased the half-life, which 




Table 1.1 Commonly Used Polymers and Fusion Proteins to Increase Half-life 
 
As an alternative to PEG, an XTEN protein has been fused to the N- or C-terminus of 
protein drugs to increase their hydrodynamic radius and half-life.43,47 The XTEN protein is an 
unstructured protein with a random sequence composed of six amino acids, including Ser, Thr, 
Glu, Gly, Pro and Ala. The XTEN sequence is normally genetically engineered into the DNA 
sequence of a functional protein, and the fusion protein is expressed in an inline homogeneous 
fashion. The XTEN sequence is biodegradable and, yet, it has been designed to prevent 
proteolysis by serum proteases for an extended period of time.57 XTEN has been incorporated 
into many functional proteins, including exenatide, human growth hormone, and glucagon to 
display half-lives with a 60- to 130-fold improvement over the native molecule.44,46,57,58 An in-
depth review of this type of fusion proteins is outside the context of this review but can be found 
at the references listed here.59,60 
Another way to improve the protein half-life is to fuse a functional molecule, such as the 




Weight (kDa) Function 
PEG Polymer of ethylene oxide  5, 10, 20 kDa Synthetic polymer34,39 
ELPfusion (Val-Pro-Gly-Xaa-Gly)x Tunable 
Reversible phase 
transition40-42 




CTP C-terminal peptide from the β-subunit of hCG 




Fc Fusion Fc domain of mAb 50 kDa FcRn binding and recycling51-53 
Albufusion Human Serum Albumin 65 kDa Long serum half-life54-56 
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degradation because at the early stage of endocytosis, the Fc domain of mAbs binds to the 
neonatal Fc receptor (FcRn). Once endocytosed, the pH is lowered to 6.0–6.5, resulting in 
protonation of the histidine residues on the CH2-CH3 hinge domain of IgG. Ionic interactions 
then form between the protonated His residues and the negatively charged Glu117, Glu132 
and/or Glu135, and Asp137 residues on FcRn. The increase in binding affinity results in the 
molecule being recycled back to the surface where it can re-enter the circulation.61 Exposure to 
the extracellular space at pH 7.4 reduces affinity and enables release of IgG from FcRn, which 
substantially lengthens circulating half-life, in some cases up to 1–2 weeks.62-64 As an example, 
etanercept (Enbrel®, Amgen) is a fusion protein consisting of two extracellular domains of tumor 
necrosis factor (TNF) receptor conjugated to the Fc fragment from IgG1. This fusion protein is 
used to treat rheumatoid arthritis by neutralizing and reducing the TNF cytokine levels produced 
during inflammation. Etanercept has a half-life of 68 h, and requires twice weekly dosing 
compared to the unstable TNFR p75 monomer.65 Also, Eloctate® (Biogen) is a recombinant 
human factor XIII fused to the Fc domain used for treatment of hemophilia. Fusion of Factor 
XIII to the Fc domain increases the half-life to 19 h compared to 8–12 h for the parent Factor 
XIII; this is due to lower elimination and slower proteolytic degradation of Factor XII-Fc fusion 
than the parent Factor XIII.66 Similar to Fc fusion, albufusion is an inline fusion between human 
serum albumin (HSA) and a bioactive protein.54 Albufusion of IFN-a (HSA-IFN-a) provides a 
longer half-life (159 h) than PEGylated IFN-a; therefore, HSA-IFN-a can be dosed every 2–4 
weeks rather than once a week for PEGylated IFN-a.56 Although the half-life of HSA-IFN-a is 
increased, its activity is only 1% of that of the parent IFN-a, similar to PEGylated IFN-a. An 
alternative to albufusion, bioactive protein can be linked to fatty acid chains, and this 
modification enables binding of the fatty acid-protein conjugate to HSA in the systemic 
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circulation. This method improves the half-life of the conjugate in the systemic circulation 
without sacrificing the activity of the protein drug.55 One example is liraglutide, a fatty acid 
conjugate of GLP-1. This conjugate binds to albumin and increases its half-life to 10–14 h.17,67 
Table 1.2 is a list of bioactive protein drugs that utilize chemical and fusion protein 
modifications to increase proteolytic stability and half-life in systemic circulation.  
 Addition of a small stability tag to a protein can increase protein enzymatic stability in 
serum while maintaining its bioactivity. In this case, the tag is a string of amino acids that is 
resistant to serum proteases. One example of an enzymatic-resistant peptide is a twelve-residue 
peptide that is resistant to thrombin proteolysis. Pro, Ser, Thr, and Asn residues within the 
peptide are the most thrombin-resistant amino acids. This inhibitory property is due to the 
induced peptide secondary structure with stabilized hydrogen bondings.68 Also, a dipeptide tag 
such as the Pro-Pro motif has been shown to increase peptide stability in serum.69 Using a 
florescent tag, incubation of stable peptides in serum showed that Asp-Pro-Pro-Ser and Asp-Pro-
Pro-Glu are the most stable sequences against enzymatic degradation.69 Thus, inclusion of a 
small stability tag can increase proteolytically stability of therapeutic peptides and proteins 
without the need to conjugate them to large molecules.   
Table 1.2 Examples of Biologics Designed to Improve Half-life 




(Merck) Interferon alfa-2b 
12 kDa PEG conjugated to 
interferon alfa-2b38,70 40 h vs. 0.1-1.7 h 
Pegasys ® 
(Genentech) Interferon alfa-2a 
Pegylated (branched 40 kDa) 








N-terminal 20 kDa PEG 
conjugated to recombinant 
methionyl human granulocyte 
colony-stimulating 
factor35,36,72 
15-80 h vs. 2.6 h 
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Two extracellular domains of 
tumor necrosis factor (TNF) 
receptor conjugated to Fc 
fragment from IgG165 
Approximately 
70 h 




Fc-fusion protein66 19 h vs. 8-12 h 
VRS-859 Exendin 4-




GLP-1 analog, exenatide 
fused with XTEN864 at the 
C-terminus43 
128 h vs. 1-5 
min  







starch)73,74 10.8 h vs. 1.7  
Byetta ® 
(AstraZeneca) GLP-1 
Second amino acid Ala to 
Gly43 
2.4 h vs. 1.5-5 
min 
Victoza ® 
(Novo Nordisk) GLP-1 
Addition of C-16 free fatty 
acid17,67 
10-14 h vs. 1.5- 
5 min 
Sandostatin ® 
(Novartis)  Somatostatin 
Shortened to eight amino 
acids, Trp8 to D-Trp8, 
disulfide, Phe to D-Phe and 
Thr to reduced threoninol21,75  







Addition of XTEN to N and C 
terminus76 
30-60-fold 
increase to more 
than 131 h 
	
1.3 PROTEOLYTIC ACTIVITY AT DIFFERENT SITES  
 Oral, pulmonary, transdermal, and other non-invasive routes contain the most preferred 
sites for peptide and protein drug administration in patients; however, some of these (i.e., oral 
and transdermal) do not have effective sites for delivering peptides and proteins due to the 
presence of restrictive biological barriers (i.e., intestinal and skin barriers) that the drugs are 
unable to cross. In addition, each delivery site has a unique composition of proteases that can 
digest the delivered peptide and protein drugs. Therefore, understanding protease activity and 
specificity for the delivered drug at the common sites of administration (i.e., intravenous, oral, 
pulmonary, subcutaneous, and transdermal) enables selection of the appropriate route of 
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administration for the drug. The drug formulation can be designed to stabilize the molecule 
against proteolytic degradation at the site of delivery (Table 1.3 and Table 1.4).77,78   
1.3.1 Intravenous Delivery 
 Intravenous injections are commonly used for direct delivery of drugs to the systemic 
circulation and to enable rapid onset of action by the biologic. Small proteins and peptides, 
specifically peptide hormones, are susceptible to rapid degradation in the systemic circulation. 
Peptide hormones (e.g., GLP-1 and glucose-dependent insulinotropic polypeptide (GIP)) exhibit 
cleavage of the first two N-terminal residues by DPP-IV in serum (Figure 1.3 A).79-81 
Furthermore, carboxypeptidase M removes the C-terminal Arg residue of GLP-1.79 DPP-IV and 
fibroblast activation protein (FAP) readily digest fibroblast growth factor 21 (FGF21) at the N- 
and C-termini, respectively, to limit its half-life to 1–2 h.82-84 Cleavage of the first 2 or 4 residues 
of FGF21 by DPP-IV did not impact its activity; however, cleavage of the C-terminus after Pro-
171 by FAP renders FGF21 inactive because it no longer binds to the receptor (Figure 1.3B).81  
	
Figure 1.3 Multiple proteolytic sites are present within protein and peptide therapeutics. Sites of enzymatic 
cleavage are labeled within (A) GLP-1,16,17 (B) FGF-21,81 (C) hinge domain of IgG1,85 and (D) MMAD payload 
conjugated to an antibody.86 
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 Large proteins such as monoclonal antibodies (mAbs) spend a substantial amount of time 
in circulation and have prolonged exposure to proteases. Degradation of mAbs is common in 
human serum; for example, IgG1 is cleaved at the hinge region by matrix metalloproteinase-3 
(MMP-3), glutamyl endopeptidase I, and streptococcal immunoglobulin-degrading enzyme 
(IdeS) to release a 135 kDa fragment (Figure 1.3 C).85 A long enzymatic incubation of intact 
mAbs leads to further proteolysis and release of Fab and Fc fragments. The antibody-drug 
conjugate (ADC) trastuzumab is susceptible to degradation by multiple proteases. For examples, 
MMPs cleave trastuzumab at the lower hinge region while IdeS cleaves between the Gly236 and 
Gly237 residues at the hinge region. When proteolysis occurs, the activity of the molecule is in 
jeopardy, which impacts both the binding to the HER2+ receptor and hinders the antibody-
dependent cell-mediated cytotoxicity (ADCC) activity. Cleavage of trastuzumab at the hinge 
domain did not affect its binding affinity for HER2; however, the ADCC activity of trastuzumab 
decreased from 80% to 20% because of the loss of the Fc domain.87 Other mAbs such as 
infliximab and adalimumab are degraded by MMP-3 and MMP-12 when incubated in sera from 
patients. A 32-kDa Fc monomer was released from the antibody, while the antigen-binding 
domain (Fab) activity was still retained for neutralizing tumor necrosis factor in patients with 
inflammatory bowel disease.88 The small Fab fragment is likely to have a shorter half-life and 
lowering circulation time for exerting its biological activity. Not only can both the mAb and the 
linker be enzymatically degraded, the drug payload itself is susceptible to degradation. 
Monomethyl auristatin D (MMAD) conjugated through a non-cleavable linker to the mAb was 
cleaved by proteases to release a 186 Da fragment corresponding to the C-terminal dolaphenine 
residue (Figure 1.3 D).86 Modification of the C-terminal end of MMAD or changing the site of 
MMAD conjugation eliminated proteolytic degradation. LC-MS techniques have been developed 
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to characterize the exact sites of proteolysis, enabling identification of specific enzymes that 
show high activity. 89-91  
1.3.2 Oral Delivery 
 One of the major hurdles in oral delivery of peptides and proteins is the harsh chemical 
and enzymatic environment of the stomach and intestines, as well as the presence of intestinal 
barriers that block the passive diffusion of peptides and proteins. The small intestine is home to 
some of the highest concentrations of proteases, including trypsin, chymotrypsin, and elastase; 
these enzymes specifically recognize and cleave basic and aromatic amino acids.8 In addition to 
proteolytic degradation, the innate physicochemical properties (i.e., size, hydrophilicity, and 
charge) of biologics prevent their absorption and permeation through the intestinal epithelium, 
which limits absorption of molecules greater than 500–700 Da.92,93 
 Upon oral administration, protein therapeutics first encounter the severe environment of 
the stomach, which has a low pH between 2–3 and contains digestive enzymes such as pepsin 
that rapidly cleave the peptide bonds. Protein and peptide drugs can be protected from the acidic 
and enzymatic environment in the stomach through complexation with pH-responsive 
complexation gels. For example, polymers can be used to encapsulate insulin for protection from 
low pH in the stomach and the insulin is released from the polymer in the intestine as the pH 
increases.94 These technologies are very useful for protection of  peptides and proteins from 
degradation, but they do not help the absorption process of peptides and protein because the 
normal bioavailability of biologic drugs is less than 1%. An alternative is OptiGelTM 
Biotechnology (Catalent), which formulates macromolecules with an enteric coating and 
permeability enhancers to protect drug molecules from degradation. This application enables 
improved drug transport through the tight junctions of the intestinal lumen. Another option to 
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decrease proteolysis is to administer the biologic with protease inhibitors; the extent of 
degradation was decreased when the ratio of inhibitor-to-trypsin was increased.95 Salmon 
calcitonin (sCT) is rapidly degraded in the lumen by serine proteases, and co-administration with 
ovomucoids greatly improves its stability. After a 1-hour incubation of 1:4 trypsin:inhibitor with 
sCT, 87% of sCT remained intact compared to 0% intact in the absence of inhibitor.95  
 From the stomach, the biologic travels to the small intestine, which consists of the 
duodenum, jejunum, and ileum. In the duodenum, enzymes secreted from the pancreas account 
for the highest proteolytic activity, while less proteolytic activity is seen in the ileum and colon.96 
Specifically, serine endopeptidases and carboxypeptidases such as trypsin, chymotrypsin, 
elastase, and carboxypeptidase A and B are secreted into the lumen.97 For bioavailability, the 
intact biologic must reach the systemic circulation, which means traversing the intestinal 
epithelium, consisting of a mucosal layer, followed by the brush-border that lines the epithelial 
cells. The mucosal layer consists of enzymes, mucopolysaccharides, glycoproteins, electrolytes, 
and water, creating a thick barrier layer that is very difficult to diffuse through, slowing 
absorption.77 Following uptake into the mucosal layer, the biologic encounters the surface of the 
epithelia cells known as the brush border membrane. Brush border enzymes have an activity of 
4.18 nmol hydrolysis/cm2/min in an area of 0.5–2.0 cm2, which was determined by cleavage of 
the substrate L-leucine-p-nitroanilide.9 Woodley et. al. have presented a complete list of active 
brush border enzymes.97  
 Antibodies have not yet been delivered orally because of their size and proteolytic 
susceptibility. An alternative to delivering intact mAbs is to use a smaller version of an antibody, 
termed a nanobody. The nanobody was initially discovered in camel sera98 and consists of a mAb 
that lacks the CH1 domain and the light chain, containing only one heavy variable chain 
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(approximately 15 kDa).99,100 Oral delivery of these molecules is of interest because of their 
small size and the fact that when incubated with pepsin or trypsin for 1 hour the molecule retains 
60% activity.101 Through DNA shuffling to create a mutant of the nanobody, proteolytic stability 
was increased and activity was retained in gastric and jejuna fluid to create a promising 
candidate for oral delivery.102 However, it is still not clear whether nanobodies can cross the 
intestinal mucosa barrier into the systemic circulation. Peptides have been used successfully to 
target cells within the intestine without the need to cross the intestinal mucosa barrier. 
Linaclotide, a 14-amino acid peptide, has been used to treat irritable bowel syndrome (IBS) and 
chronic idiopathic constipation (CIC). The peptide targets a receptor within the intestine to 
stimulate a pharmacologic response without requiring exposure to the systemic circulation. 
Rapid proteolysis of linaclotide was observed in the duodenum and jejunum, and less 
degradation was observed in the ileum.103 When linaclotide was incubated with carboxypeptidase 
A, a single reaction product was formed, but the molecule remained active.103 Other peptides, 
such as GLP-1 agonists for oral formulations were in phase I or II clinical trials in 2015104 and 
insulin for oral formulations was in phase II-IV clinical trials as reported in 2016.93 
1.3.3 Pulmonary Delivery  
 Pulmonary delivery is a non-invasive option that avoids the harsh condition of the GI 
tract. The lung provides a large surface area with good vascularization and low membrane 
thickness, making it an ideal drug delivery site. Although the characteristics of the lungs seem 
well suited for delivery, mechanisms are in place to keep out foreign substances. Absorption is 
difficult to achieve because of the presence of alveolar macrophages and proteases in the lower 
respiratory airways designed to remove toxic aerosols.105 The main clearance mechanism in the 
upper conducting airways is mucociliary clearance using a mucus layer. The mucus layer 
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protects the body from foreign inhaled substances that are rapidly cleared before reaching the 
epithelium. Drugs that cannot penetrate the mucus layer will be eliminated with the mucus when 
it is transported by the ciliated cells to the GI tract.106 The lower respiratory airways contain 
alveolar macrophages and proteases that clear or degrade slowly dissolving molecules.107 
Macrophages contain peptide hydrolases that can degrade foreign proteins rapidly, evolving this 
function as a protection against foreign bacteria and viruses. Enzymes such as extracellular 
lysozyme, aprotinin, neutral endopeptidase, angiotensin-converting enzymes, tryptase, and 
chymase are active in the pulmonary environment.108 Most of these enzymes are non-specific 
and cleave at many peptide bond sites. If the biologic makes it past the mucus layer, it will 
encounter the epithelium, where the molecule can be absorbed by transcytosis or paracellular 
transport or through large pores in the epithelium.109 Lastly, the molecule must pass through the 
basement membrane and vascular epithelium, which are cells that make up the small blood and 
lymph vessels enabling access to the systemic circulation.110,111  
 Enzymatic degradation is common during pulmonary delivery, but to a lesser extent than 
in oral delivery. Comparison of incubation of insulin in small intestine homogenate vs. 
homogenate of lung tissue showed half-lives of 66 min and 82 min, respectively.112 These results 
are in line with insulin incubation in intestinal epithelial cytosol compared to lung cytosol where 
60% of insulin remained intact after 9.1 and 27 min, respectively.113 When co-administered with 
bacitracin, an inhibitor of aminopeptidases, 95% and 60% of insulin remained intact after 10 and 
240 min, respectively, while only 65% intact insulin remained after 10 minute-incubation 
without bacitracin.113 Other proteins have been investigated for enzymatic degradation via the 
pulmonary route.114 For example, formulation of sCT into PEG-coated micelles shielded the 
peptide from enzymes in the pulmonary environment and increased bioavailability by 60%.115  
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Similarly, peptide YY (PYY; a 36-amino acid peptide), which is used to treat obesity by 
suppressing appetite, has the same half-life when administered via the pulmonary (25 min) and 
intravenous (26 min) routes.116 One metabolite of PYY is PYY3-36 with deletion of the first two 
amino acids. This deletion suggests that DPP-IV is the cause of the N-terminal cleavage in 
PYY.116  
1.3.4 Subcutaneous and Transdermal Delivery 
 Subcutaneous injection using a needle to administer a bolus injection into the hypodermis 
is commonly used to deliver biologics because it bypasses the protective layers of skin (i.e., the 
stratum corneum, epidermis, and dermis) that contain many proteases for protection from foreign 
substances.117 The drug travels to the systemic circulation either by traversing the blood vessels 
or through lymphatic uptake. Proteolysis also occurs at the subcutaneous site, and co-
administration of enzyme inhibitors suppresses degradation of biologics. For example, co-
administration of the protease inhibitor e-aminocaproic acid decreased proteolytic activity to 
restore response to the parathyroid hormone (PTH).118  
A less invasive strategy is transdermal delivery; it has the convenience of self-
administration and less frequent dosing, which increases patient compliance. Transdermal drug 
delivery encounters less proteolytic activity than mucosal routes.119 Enzymes that are active 
throughout the skin layers include endopeptidases and exopeptidases. Carboxypeptidases and 
aminopeptidases are specifically found in the skin; they metabolize collagen, gelatin, and elastin 
as well as exopeptidases, such as DPP-IV, carboxypeptidases, and aminopeptidases.120 
Streinstrasser et al. list enzymes that cleave topically applied peptides, including aminopeptidase 
and dipeptidyl peptidase that digest calcitonin and vasopressin.120 The GLP-1 analog, exendin-4, 
was investigated for transdermal delivery. Exendin-4 has a half-life of 30 min when administered 
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intravenously and 2–3 h when administered subcutaneously. To improve the half-life, two Cys 
mutants were placed within exendin-4 at i and either i +7, i +11, or i +14 to create a disulfide 
staple to stabilize the helical structure and protect against serum proteases. Microstructure arrays 
consisting of exendin-4 incorporated into biodegradable solid microstructures allow more rapid 
systemic absorption, reaching Cmax after 5 min compared to the gradual increase over 8 h 
observed with subcutaneous administration.121 Although transdermal delivery has lower 
proteolytic activity, analogs such as exendin-4, rather than GLP-1, must still be used to protect 
against active proteases. 
Table 1.3 Proteases Expressed at Each Site of Administration 
Sites Proteases Solutions 
Intravenous 
DPP-IV, FAP, MMPs, IdeS, Glutamyl 
endopeptidase I, plasmin, 
carboxypeptidase M 
Amino acid mutations17,18 
Oral 
Pepsin, carboxypeptidase A, plasmin, 
trypsin, carboxypeptidase B, 
chymotrypsin, elastase 
Polymer enteric coating,94 
thioether cross-linkage,122 
enzyme inhibitors95 




Transdermal Neutral endopeptidase 24.11, DPP-IV 
Disulfide staple,121 
enzyme inhibitors118 
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1.4 TARGETING PROTEASES FOR IMPROVED DELIVERY 
1.4.1 Protease-Activated Therapeutics  
 Although inhibition of proteases is often necessary for the biologic to reach or be retained 
in the systemic circulation, proper timing of the release at the tumor site presents an advantage to 
create extremely effective biologics. For example, ADCs utilize cleavable linkers that take 
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advantage of the differences in intra- and extracellular environments, such as reduction potential 
and the specific enzymes expressed at each site. The conjugation between the two entities by a 
linker is extremely important because it determines the stability of the intact molecule. Ideally, 
the linker is stable in the systemic circulation before reaching the target cells, yet the payload is 
released once the conjugate is internalized into the cell.131 It is necessary to characterize the 
stability of the intact ADC to ensure that limited premature drug release occurs to avoid off-
target toxicity.132 Different types of linkers such as chemically-labile, enzymatically-labile, and 
non-cleavable linkers are used for conjugation.131 Linkers are typically compared to determine 
the most stable and useful linker for the specific application.133 Conjugation of a mAb to MMAE 
through a hydrazone (acid-labile) linker was compared to conjugation through a dipeptide 
(enzyme-labile) linker. The enzyme-labile linker showed increased stability in plasma, and 
further investigation using a mouse model determined half-lives of 2.3 days and 30 days for acid-
labile and enzyme-labile linkers, respectively.134 
 Within lysosomes there are more than 50 hydrolytic enzymes that thrive in the acidic 
environment, completing rapid degradation by proteolysis.135 Cathepsins are lysosomal enzymes 
and are classified as serine, aspartic, and cysteine cathepsins. In addition, other enzymes such as 
napsin and AEP (asparagine endopeptidase) are present.135 During disease states, levels of 
protease expression and activation are dysregulated, making proteolysis within the tumor 
environment unpredictable.136 For example, not only are cathepsins found intracellularly, but 
during tumor metastasis they are secreted into the extracellular environment where they degrade 
extracellular matrix (ECM) proteins.137 A popularly used enzymatic linker is the valine-citrulline 
(vc) dipeptide that is cleaved intracellularly by cathepsin B.123 Alternatively, a b-glucuronide 
linker is cleaved by b-glucuronidase, an enzyme expressed in lysosomes and the tumor 
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environment.124 Choi et. al. provides a list of intracellular proteases and their preferred cleavage 
sequence, including enzymes such as cathepsin B, kallikrein 2, MMPs, and trypsin.2  
 Targeted release within the tumor environment rather than intracellularly has been used 
successfully as well. One family of enzymes that is of interest is MMPs because their 
dysregulated activity is associated with tumorigenesis. Doxorubicin (DOX), a small molecule 
chemotherapeutic agent, was conjugated to a small peptide consisting of an MMP cleavage 
sequence. The attached peptide inhibited DOX from diffusing into the cell, but after proteolytic 
removal of the peptide, the molecule is free to enter the cell and increases DOX accumulation at 
the tumor site 10-fold compared to that in other tissues.138 The enzyme chosen to cleave the 
prodrug should be expressed solely at the site of desired activation to create an effective prodrug. 
This is truly a way to improve selectivity of a molecule by targeting well-known enzymes 
expressed only at the targeted site.  
1.4.2 Enzymatic Releasable Half-life Enhancement 
 As discussed above, half-life can be improved through chemical conjugation or fusion of 
a polymer to the protein, but often these polymers impede bioactivity. A releasable version of 
PEG has been used to control and modify the half-life of the molecule and allow the free 
molecule to retain activity once released.39,139,140 This technology is extremely useful for 
applications in which addition of PEG greatly reduces activity. The design includes an enzymatic 
cleavage sequence between the biomolecule and PEG.141 For example, the antimicrobial peptide 
Onc112 was conjugated to PEG through a 4-residue linker that is recognized and cleaved by 
blood proteases. Depending on the sequence of the linker, the half-life can be tuned anywhere 
from 1 to 42 h for Onc112.142 Releasable methods were also applied to the albufusion 
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technology, where HSA is released by proteolysis from the protein therapeutic. This releasable 
technology exhibits a 2- to 64-fold increase in activity over the non-releasable construct.73  
 Alternatively, enzyme-releasable small affinity tags to human serum albumin, termed 
albumin binding domains (ABDs), can be used to bind to serum albumin. Albumin binding 
domains of 12 amino acids were identified to bind with high affinity to HSA. Similar to the 
releasable albufusion technology, the addition of a linker containing a thrombin or Factor Xa 
cleavage sequence can be used to release the ABD peptide. An ABD-linker-GLP-1 molecule was 
created and an 8–20-fold improvement in half-life of exendin-4 was observed.143 Conjugation 
through enzymatic linkers allows slow release of proteins from their circulating half–life 
partners.  
1.5 CONCLUSIONS 
 Proteolysis is an important factor to consider when designing biologics. Proteolysis can 
cause a short half-life by cleaving the biologic into smaller fragments or site-specific cleavage 
that causes inactivation. Both amino acid sequence and secondary structure impact the ability of 
a protease to cleave a protein, and new techniques are being developed to easily impose and 
stabilize protease-resistant structures. Large fusion proteins can be added to proteins to increase 
their half-lives, but they often compete with the activity of the molecule. Using enzymes to 
purposefully cleave a prodomain to release an active protein allows “tuning” of the half-life of 
these biologics. Strategies to protect biologics from proteolytic degradation can be implemented 
to successfully design active and effective biologics.  
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CHAPTER 2. THIOREDOXIN FUSION CONSTRUCTS ENABLES HIGH-YIELD 
PRODUCTION OF SOLUBLE, ACTIVE MATRIX METALLOPROTEINASE-
8 (MMP-8) IN ESCHERICHIA COLI 
	
2.1 INTRODUCTION 
Matrix metalloproteinases are a class of proteins responsible for degrading extracellular 
matrix (ECM) proteins to support tissue remodeling and repair.1,2 MMPs are of interest because 
of their complex biological roles and because of their participation in a variety of disease states, 
including cancer, metastasis and tumorigenesis, which is caused by the inappropriate up- or 
down-regulation of MMPs and/or their activity.3 Elevated activity leads to loosening of the 
supporting matrix, which facilitates dissemination of cancer cells to enable metastasis.4 Many 
MMP inhibitors have been created, but most have failed in clinical trials because of the complex 
set of contributions MMP activity exerts on disease progression, and as such, these enzymes 
remain the subject of much study.5,6  
MMPs utilize a zinc-bound metal active site and are secreted as glycosylated zymogens, 
with a prodomain bound to the metal active site.2 Catalysis is activated by proteolytic cleavage of 
the prodomain, which exposes the active site. These enzymes are often difficult to produce 
recombinantly in a soluble form because of their complex composition, and generating them 
typically requires numerous steps, which include expression as proenzymes, refolding and use of 
several diverse purification approaches.7-9 MMPs also are difficult to produce because of their 
proteolytic function, which permits autoproteolysis to occur.10 Significant efforts have resulted in 
the production of a few MMPs in the amounts necessary to study their structure in atomic 
detail.11-14 Crystal structures of MMP-8 have been solved (PDB: 3DNG, 3DPE, 1ZVX)15,16 
utilizing the complex protein production methods, and moreover, require the addition of an 
inhibitor to prevent autoproteolysis when concentrated.17 The ability to obtain high-resolution 
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information about the protein enables design of selective inhibitors and provides the ability to 
characterize other ligand and protein-protein interactions that regulate enzyme activity.18-20 
MMP-8 plays a role in cancer, arthritis, and asthma and promotes premature degradation 
of dental fillings by degrading the underlying collagen matrix within the dentin of demineralized 
tooth.21,22 While the fold of MMP-8 is related to other MMPs, it differs from them in the active 
site because it contains an insertion that creates a significantly larger binding pocket.23 The 
ability to study this enzyme and its unique active site in atomic detail in solution, without using 
an inhibitor would be extremely valuable for simplifying production and understanding how to 
design more potent and selective inhibitors of this particular MMP.24,25  
Here, we present a method to express an active, stable form of matrix metalloproteinase-8 
(MMP-8) in E. coli in sufficient amounts to enable structural evaluation. Several fusion 
constructs were generated that did not result in high yield of soluble, active, stable protein, but 
one construct met these criteria. This MMP-8 fusion includes two tags (thioredoxin and S Tag) to 
aid in folding and stability and a polyhistidine tag for affinity purification. Using this system, 
over 100 mg of MMP-8 from a 1 L cell culture can be expressed as a fusion protein in the 
soluble fraction of the cell lysate and purified quickly using immobilized metal affinity 
chromatography (IMAC) to recover appreciable amounts of catalytically active enzyme that 
retains full activity when stored refrigerated in simple buffer. Recognition sites for removal of 
the thioredoxin and thioredoxin-S Tag fusion partners were engineered into the construct. A 
spacer sequence also containing the metal-binding claMP Tag was inserted between the fusion 
partner and the enzyme. An additional aim of this study was to demonstrate compatibility of use 
of the metal abstraction peptide (MAP) technology inline with a metalloprotein.26 Genetic 
engineering of MAP into a plasmid creates, the claMP Tag, a linker-less carrier for many 
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transition metals with utility in healthcare applications.27 The claMP Tag is a tripeptide 
consisting of the amino acid sequence Asn-Cys-Cys, which scavenges small transition metals 
from chelating agents.28 Because of the uniquely beneficial properties of the claMP Tag, which 
includes extraordinarily tight binding, resistance to metal release upon dilution at serum pH and 
specific release in acidic conditions as in endosomes, the claMP Tag is being investigated as a 
method for targeted delivery of metals for therapeutic and diagnostic applications by designing 
targeting proteins to contain the metal bound tripeptide.27 The claMP Tag has not been 
investigated previously in a system, such as matrix metalloproteinases, in which a structural 
and/or catalytic metal-binding site is present. Analysis of the activity and stability of these two 
fusion proteins and their cleaved products is presented herein. 
2.2 MATERIALS AND METHODS 
2.2.1 Genetic Engineering   
Human matrix metalloproteinase-8 (MMP-8) in the pCMV6-XL4 vector was obtained 
(OriGene Technologies, Inc. Cat # SC 127843) and the catalytic domain was amplified with 
designed primers (Integrated DNA Technologies). Two constructs of MMP-8 were prepared, one 
containing solely MMP-8 and one bearing an additional N-terminal claMP Tag (Asn-Cys-
Cys).27,29 The primers contained a region matching the pET-32Xa/LIC vector (underlined), a 
portion matching the MMP-8 catalytic domain (italics), the claMP Tag (bold) and an inserted 
linker (bold and underlined) between the claMP Tag and MMP-8. 5’-GGT ATT GAG GGT 
CGC AAT CCA GGA AAC CCC AAG TG-3’ (forward primer no claMP Tag), 5’-TGC GGC 
TCT TCT GGC ATT GAG GGT CGC AAC CCC AAG TGG GAA-3’ (first forward primer for 
claMP-link insertion), 5’-GGT ATT GAG GGT CGC CCA GAT CTG GGT AAC TGC TGC 
GGC TCT TCT GGC-3’ (second forward primer for claMP-link insertion), and 5’-AGA GGA 
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GAG TTA GAG CCT TAT CCA TAG ATG GCC TG-3’ (reverse primer for both constructs). 
The MMP-8 PCR reaction was purified using QIAquick PCR Purification Kit (Qiagen) and was 
inserted into the pET-32Xa/LIC vector by ligation independent cloning (protocol provided by 
Novagen). claMP-link-MMP-8 required two sequential PCR steps to incorporate the full-length 
linker. The PCR reaction was then purified using QIAquick PCR Purification Kit (Qiagen) and 
was inserted into the pET-32Xa/LIC vector by ligation independent cloning (protocol provided 
by Novagen). The inserted tag contained a BglII site so that the original Factor Xa recognition 
sequence could be removed by cleaving with this endonuclease. The new plasmid was cut with 
the restriction enzyme, BglII and was re-ligated with T4 DNA ligase.  
Using the standard heat shock procedure, the reactions were transformed into DH5α 
Escherichia coli (E. coli) cell strain. Luria broth (LB) agar plates with 100 µg/mL ampicillin 
were used to select transformed cells. The plates were incubated overnight at 37 °C. Individual 
colonies were grown in 5 mL LB with 100 µg/mL ampicillin overnight at 37 °C and 250 rpm. 
The starter cultures were spun down at 1717 x g for 15 min and the supernatant was discarded. A 
miniprep kit (Qiagen) was used to purify the plasmid DNA. DNA sequences were confirmed by 
UC Berkeley DNA Sequencing Facility.    
Four additional constructs bearing a variety of tags that may improve folding and/or 
solubility were generated and tested for expression in E. coli. These constructs did not lead to 
accumulation of soluble protein and are described in Supplemental Information.   
2.2.2 Expression of MMP-8 
Plasmids were transformed into BL21 E. coli cell strain using standard heat shock 
techniques. The cells were plated on LB agar plates with 100 µg/mL ampicillin and incubated 
overnight at 37 °C. Cultures were started using a single colony to inoculate 50 mL of LB with 
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100 µg/mL ampicillin and grown for 16 h at 37 °C, 250 rpm in an orbital shaker. Twenty 
milliliters of starter culture was transferred to 1 L of LB with 100 µg/mL ampicillin in a 3 L 
fernbach flask. The cells were grown at 37 °C, 250 rpm until the OD600 reached approximately 
0.7. One milliliter of 1 M isopropyl β-D-1-thiogalactopyranoside (IPTG) was used to induce the 
cells, which were harvested after 4 h by centrifugation at 1391 x g for 8 min. The cell pellets 
were stored at -80 °C until use. 
2.2.3 Protein Purification 
A one-liter pellet was resuspended in 25 mL lysis buffer (50 mM Tris-Cl, 20 mM 
imidazole, 59 mM NaCl, 10 µM N-Isobutyl-N-(4-methoxyphenylsulfonyl)glycyl hydroxamic 
acid (NNGH), pH 7.9) and three passes through a french press at 21,000 psi was used to lyse the 
cells. Lysates were centrifuged for 1 hour at 21,000 x g and 4 °C. The supernatant containing the 
protein was filtered through a 0.45 µm filter followed by a 0.2 µm filter and applied to a 
nickelated 5 mL Hi-Trap Chelating HP column (GE Lifesciences) equilibrated in lysis buffer. 
The column was washed with 50 mM Tris-Cl, 58 mM NaCl, 40 mM imidazole, 10 µM NNGH, 
pH 7.9 for 10 CV at a flow rate of 1.25 mL/min at 4 °C. The protein was eluted from the column 
using a linear gradient elution starting with the wash buffer (50 mM Tris-Cl, 58 mM NaCl, 40 
mM imidazole, 10 µM NNGH, pH 7.9) and increasing the imidazole concentration from 0 to 
100% of 50 mM Tris, 37 mM NaCl, 500 mM imidazole, 10 µM NNGH, pH 7.9. The eluate was 
concentrated using Amicon Ultra 10 kDa MWCO (Millipore) concentrators to approximately 2 
mL and injected on a HiLoad 26/600 Superdex 75 prep grade column (pack size 1 x 320 mL, GE 
Lifesciences #28-98930-34) equilibrated in 50 mM Tris-Cl, 60 mM NaCl, 10 µM NNGH, pH 7.9 
to separate degradation fragments and eliminate the imidazole in the sample. The fractions 
containing the protein were concentrated using an Amicon Ultra 10 kDa MWCO (Millipore) to 
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approximately 2 mL. To cleave the fusion into thioredoxin and S Tag-MMP-8, 70 Units of 
Thrombin were added and the reaction was incubated at room temperature for 12 h. The sample 
was injected on a Superdex 75 column (GE Lifesciences) to separate the fragments. The S tag 
was cleaved by adding 9.8 ng of Factor Xa and allowing the reaction to proceed at room 
temperature for 16 h and run over the Superdex 75 column (GE Lifesciences). The final product 
was concentrated to 1.5 mL and stored at 4 °C. All solutions used in these procedures contained 
10 µM NNGH to stabilize the protein and protect against autoproteolysis, however, it was 
determined herein that this compound is not required for the fusion proteins. 
claMP-link-MMP-8 abstracts nickel from the IMAC resin during purification, generating 
a translucent, rusty orange solution, typical of the Ni-claMP complex.27 As previously reported, 
UV-vis absorbance spectroscopy at 425 nm was used to assess metal occupancy of the claMP 
Tag in the fusion construct.27 The molar extinction coefficient for 425 nm is 350 M-1cm-1. 
Following purification, at 0.5 mM, the highest concentration of the fusion protein, the A425 
indicates complete nickel insertion into the claMP Tag has been achieved. Factor Xa cleaves the 
nickel-bound claMP Tag from MMP-8. 
2.2.4 Liquid Chromatography and Mass Spectrometry 
Whole protein electrospray ionization mass spectra (ESI-MS) were acquired on a Qtof 
Premier (Waters/Micromass, Manchester UK) hybrid mass spectrometer operated in MS mode 
and acquiring data with the time of flight analyzer. The instrument was operated in V mode or at 
9000 resolution. The source was optimized using lysozyme infused at the HPLC flow rate. The 
cone voltage was 45 V, the source ion guide with added gas flow (N2, 20 mL/min) and Ar was 
admitted to the collision cell. The cell was operated at 10 eV or maximum transmission without 
increasing water loss ions. Spectra were acquired covering the mass range 300 to 3000 amu and 
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accumulating data for 4 seconds per cycle. Time to mass calibration was made with NaI cluster 
ions acquired under the same conditions. Spectral mass correction was made with the peptide 
leucine encephalin (YGGFL) dimer (1111.5463) observed in the lock mass spray channel. The 
average mass of proteins was determined from the charge state distribution with the "Transform" 
and/or MaxEnt I routines in Masslynx software.  
Microbore HPLC/MS experiments were performed with a Waters Acquity H class 
chromatograph at 180 µL/min on a 1-mm ID C4 RP column eluting into the standard ESI source 
of the Qtof premier. The solvents were: A H2O, B 90% CH3CN, 10% isopropanol, both 0.08% 
formic acid. Separations were performed on a 1-mm ID x 50-mm long C4 reverse phase column 
(Zorbax C4, 300Å pore size, 3.5 µm particles packed by Micro-Tech) with a 1-mm x 2-cm dry-
packed guard column (Upchurch Scientific Model C.128, Oak Harbor, WA) filled with Zorbax 
C3 resin. The gradient was to ramp from 1% to 20% B in 1 min then to 50% B by 9 min, and 
finally to 75% B by 10 min. 
2.2.5 Circular Dichroism Spectroscopy 
 Circular dichroism (CD) spectra were collected using a Chirascan spectropolarimeter 
(Applied Photophysics). The samples were analyzed at a concentration of 0.2 mg/mL in 10 mM 
sodium phosphate, pH 7.9 and were added to a quartz cuvette with a 0.1-cm path length (Starna 
Cells). Spectra were collected at 10 °C and analyzed using several wavelength ranges, beginning 
at 190, 195, 200, 205 and 210 nm through 260 nm. Background signal from the solution was 
subtracted. CDNN software (Applied Photophysics) was used for spectral deconvolution.  
2.2.6 SDS PAGE Analysis 
SDS-PAGE samples were obtained by mixing 30 µL of sample with 30 µL of reducing 
Laemmli buffer and heated at 90 °C for 10 min. Samples were stored at -20 °C until used. Gel 
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samples were loaded onto standard 15% (v/v) resolving, 4% (v/v) stacking gels and run at 135 V 
for 2 h. A pre-stained molecular weight ladder (BioRad, #161-0374) was used for Coomassie 
staining and an unstained molecular weight ladder (BioRad, #161-0363) was used as a reference 
for gels stained with SYPRO Ruby Protein Gel Stain (Life Technologies, cat# S-12000).  
2.2.7 Densitometry Analysis 
Densitometry analysis was done on SYPRO Ruby-stained gels. A Typhoon TRIO 
Variable Mode Imager (Amersham Biosciences) was used to image the gels and ImageQuantTL 
Software was used to perform the quantitative analysis. Gels were stained with SYPRO Ruby 
Protein Gel Stain (Life Technologies, cat# S-12000) according to the manufacturer’s 
instructions.  
2.2.8 Activity Assay  
The MMP-8 Fluorometric Drug Discovery Kit, RED (Enzo Life Sciences cat# BML-
AK305) was used to examine enzyme activity of the recombinant proteins and cleavage 
products. The kit components were thawed to room temperature and diluted in assay buffer 
according to the manufacturer’s instructions. Briefly, assay buffer, enzyme (final concentration 1 
µM), and either inhibitor (final concentration 5 µM) or an equivalent amount of buffer were 
pipetted into the wells of a 96-well plate and incubated at 37 °C for 1 hour. The fluorescent plate 
reader was set at Ex/Em=545/576 nm, with cut off at 570 nm. To begin the reaction, 10 µL of 
substrate equilibrated to 37 °C was added to obtain a final concentration of 1 µM. Buffer blanks 
and control solutions were analyzed to account for background signal and samples were analyzed 
in triplicate. Data were processed and fitting and error analysis was performed using Microsoft 
Excel and plots were made using GraphPad Prism. Error bars are representative of the standard 
deviation between replicates. 
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2.3 RESULTS  
2.3.1 Recombinant MMP-8 Expression and Purification 
The catalytic domain of MMP-8 was cloned into a set of eight vectors containing a 
variety of tags to identify a construct that would produce soluble, active protein in high yield. 
The pET-32Xa/LIC vector containing N-terminal thioredoxin and S Tag successfully supported 
this objective. This fusion construct enables folding of MMP-8 to generate milligram quantities 
(from one liter culture) of the catalytically active enzyme while avoiding accumulation in 
inclusion bodies, which allows one-step affinity purification from the soluble fraction of the cell 
lysate.  
 To test the robustness of the general construct, an additional variant of the MMP-8 fusion 
protein was created that alters the spacing between the stabilizing fusion partner and the enzyme. 
The claMP Tag developed by our lab was inserted N-terminal to MMP-8 with an additional 
flexible spacer sequence (Gly-Ser-Ser-Gly-Ile-Glu-Gly-Arg) (Figure 2.1). The claMP Tag is an 
extremely stable, inline module for targeted metal delivery.27,30 It consists of the amino acid 
sequence Asn-Cys-Cys and rapidly and quantitatively binds metal at basic pH,30,31 here during 
purification upon exposure to the Ni-IMAC resin. The recognition sequence of Factor Xa follows 
this claMP-link spacer in the claMP-link-MMP-8 construct to permit cleavage of the additional 
tag and release of the same MMP-8 product. SDS-PAGE analysis of pre- and post-induction 
samples shows expression of the proteins in E. coli at the expected molecular weight of 
approximately 35 kDa (Figure 2.2). 
 
Figure 2.1 Cartoon of the fusion constructs of matrix metalloproteinase-8 (MMP-8) containing fusion 
partners and cleavage sites. 
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 A representative SDS-PAGE analysis of the purification of MMP-8 fusion is shown in 
Figure 2.3. Following cell lysis and centrifugation to remove insoluble debris, the MMP-8 fusion 
protein remained present in the soluble fraction of the cell lysate, while it was not detectable in 
the pellet (Figure 2.3, lane 2). A Ni-IMAC column was used to affinity purify MMP-8 fusion 
from the cell lysate. The flow through during application of the cell lysate to the column (lane 3) 
and the 40 mM imidazole wash (lane 4) were collected to verify retention of protein on the 
column. A gradient elution of imidazole from 40 mM to 500 mM over 12 CV was used to elute 
the protein (lane 5). The gel displays molecular weight proteins below the expected 35-kDa 
MMP-8 fusion indicative of proteolytic degradation. To remove the lower molecular weight 
fragments SEC was used (lane 6) and mass spectrometry confirmed the presence of full-length 
fusion MMP-8 (Figure 2.4). 	
	
Figure 2.2 Coomassie stained SDS-PAGE showing expression of the two different MMP-8 constructs. 
(A) MMP-8 fusion cell lysate pre-induction (lane 2) and post-induction (lane 3). (B) claMP-link-MMP-8 
fusion cell lysate pre-induction (lane 2) and post-induction (lane 3). In panels A and B, lane 1 is the molecular 
weight ladder (BioRad, #161-0374). 
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Thrombin and/or Factor Xa was/were added to the purified protein in an effort to remove 
the fusion tags and release MMP-8. Reaction with Factor Xa leads to incomplete cleavage but 
the uncut fusion protein is easily removed by SEC. Unfortunately, productive cleavage generates 
two proteins (MMP-8 and thioredoxin-S Tag) of approximately 17-18 kDa, which cannot be 
separated by SEC and attempts to isolate MMP-8 from the fusion partner using IMAC after 
Factor Xa cleavage were unsuccessful. Consequently, a serial reaction with thrombin and Factor 
Xa was performed. Thrombin was added to cleave the thioredoxin tag (13 kDa), leaving S Tag-
MMP-8 (21-kDa) (lane 7). While complete cleavage at the desired position is observed, 
additional fragments appear in the 
sample (lane 7). SEC effectively 
separates the cleaved thioredoxin 
tag (lane 10) from the MMP-8 
fusion protein (lane 8) though a 
band appears on the gel at 13 kDa 
(lane 8), it is not thioredoxin; mass 
spectrometry shows that 
thioredoxin is not present in the 
MMP-8 fraction and this band 
instead corresponds to a fragment 
of MMP-8 (mass spectrum peak at 
13875.8 ± 0.2 Da corresponds to 
MMP-8 fragmentation at residue 
72 between Ala and His, with an 
	
Figure 2.3 Coomassie stained SDS-PAGE of the purification process 
of MMP-8. (Lane 1) molecular weight standards, (lane 2) soluble fraction 
of the cell lysate, (lane 3) the flow through of application of the cell lysis 
to the Ni-IMAC, (lane 4) the flow through of a 40 mM wash of the Ni-
IMAC, (lane 5) the gradient elution peaks from 40 to 500 mM imidazole, 
(lane 6) SEC separation of degradants from the gradient elution step, (lane 
7) after incubating with thrombin for 12 h, (lane 8) separation of thrombin 
cleavage fragments by SEC, (lane 9) after incubating with Factor Xa for 
16 h, (lane 10) thrombin-cleaved thioredoxin tag separated by SEC.  
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average theoretical mass of 13876.1 Da) presumably due to autoproteolysis (data not shown). 
Multiple degradation fragments are present that would not separate using SEC. Because MMP-8 
is prone to autoproteolysis, it seems likely that degradation proceeds once thioredoxin is cleaved.  
It is evident from the higher molecular weight bands in lane 8 and mass spectrometry data that 
Factor Xa fails to accomplish complete cleavage, resulting in a mixture of S Tag-MMP-8 and 
MMP-8 in the final product (lane 9). Attempts to isolate MMP-8 by SEC after this step result in 
extremely low recovery of protein, which remains a mixture of fragments. 
Approximately 130 mg of protein was obtained from the cell lysate of a one-liter culture 
of MMP-8 fusion, determined by a Bradford assay after Ni-IMAC elution. 75 mg was injected 
onto the SEC and approximately 50% was recovered at the correct size (with fewer degradation 
fragments) (Figure 2.3, lane 6). The amount of MMP-8 obtained at each purification step was 
determined and is reported as the weight fraction of MMP-8 within the total fusion protein 
(Table 2.1). Although the results are not quantitative for cleaved MMP-8, the table summarizes 
the high-yield of protein produced in the form of the fusion construct and relative losses that 
accompany removal of the stabilizing fusion partner. The table shows that when using the 
thioredoxin-S Tag fusion construct large amounts, 20-40 mg of MMP-8 were obtained following 
affinity purification. The results show clearly that substantial loss of MMP-8 occurs when the 
Table 2.1 Relative MMP-8 Equivalentsa Recovered at Each Purification Step 





Post Factor Xa 
Cleavage (mg) 
MMP-8 39.6 ± 7.7 20.5 ± 3.7 9.8 ± 0.3 0.9 ± 0.7b 
claMP-link-MMP-8 22.2 ± 2.6 ND ND 1.2 ± 0.2b 
aMass equivalents of MMP-8 were calculated by taking the mass of MMP-8 as a fraction of the fusion protein, which 
initially was 75 mg. bThis value reflects the total protein content of cleaved fragments present, not native MMP-8. 
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fusion partner is cleaved. The percent yield of MMP-8 recovered after complete processing was 
calculated to be approximately 2.5% ± 2.3% of the original amount present in the fusion 
constructs, but this value is clearly falsely elevated because MMP-8 cannot be obtained in a pure 
form and the sample contains numerous fragments. Because these species cannot be isolated and 
their individual activity assessed, accurate quantitation of native MMP-8 is not possible. 
2.3.2 Mass Spectrometric Analysis 
The correct protein size was 
initially determined using an SDS-
PAGE analysis. To confirm the results 
from SDS-PAGE, a mass 
spectrometric analysis was completed 
of the fusion protein isolated by 
affinity chromatography. The spectrum 
shows a peak at 34971.4 ± 0.5 Da, 
which corresponds to fusion MMP-8 
with the N-terminal methionine removed (average theoretical mass = 34,973.8 Da) (Figure 2.4). 
The thrombin and Xa-cut mass spectrometry analysis displayed peaks of the expected masses but 
also many fragments of lower molecular weight, which presumably result from autoproteolysis 
(data not shown). Mass spectrometry data also was collected for the claMP Tagged fusion 
construct and it displayed the expected mass of 34893.13 ± 0.44 Da for the fusion protein lacking 
the lead methionine residue as well (data not shown).  
	
Figure 2.4 Mass spectrum of MMP-8 fusion (average 
theoretical mass of 34973.8 Da). 
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2.3.4 Circular Dichroism (CD) Analysis 
To verify the correct fold for the fusion proteins is achieved, the secondary structure of 
MMP-8 fusion and claMP-link-MMP-8 fusion was analyzed using CD. Each protein was 
determined to be folded properly, containing the expected proportion of secondary structure that 
was predicted from the structures of the individual domains for thioredoxin and MMP-8. The 
spectra of MMP-8 fusion and claMP-link-MMP-8 fusion are very similar overall, but differ 
substantially below 200 nm. Differences in this region correspond to the tag itself. The calculated 
helical content decreases by 5% and random coil content increases by approximately 5% when 
this region of the spectrum is excluded from the calculation. This region is often omitted from 
CD analysis because of interference from buffers and other components, and the values obtained 
for secondary structure calculated using 205-260 nm produces comparable results for the two 
variants, indicating the claMP Tag does not affect the fold of MMP-8. The helical content of 
MMP-8 fusion and claMP-link-MMP-8 fusion was determined to be 19% and 18%, while the b-
strand composition was 28% and 29% and random coil was 47% and 48%, respectively. This is 
consistent with previous CD analysis of MMPs, which have approximately 20% helical, 20% b-
strand and 50% random coil structures.32 The two constructs examined have an N-terminal 
thioredoxin tag, and independently thioredoxin has approximately 35% helical and 18% b-strand 
character.33 An intervening linker sequence is also present between these two domains, which 
comprises approximately 10% of the fusion protein. This region may adopt a non-random coil 
structure and lead to the great increase in stability of the fusion system. Because the structure of 
this region is unknown, the experimentally determined value of the amalgamated fusion 
secondary structures matches that expected for thioredoxin fused to MMP-8.   
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2.3.5 Densitometry Analysis of Stability  
MMP-8 fusion and purified MMP-8 were stored at 4 °C in 50 mM Tris, 60 mM NaCl, 10 
µM NNGH, pH 7.9 and sampled over several days to determine the stability of the purified 
enzymes. SDS-PAGE and densitometry analysis were performed to compare the amount of 
intact enzyme to the total protein content to determine the extent of degradation. The intact 
fusion protein represents approximately 50% of the total protein in the sample at day 1, and 25% 
of the full-length fusion protein remains after 12 days (Figure 2.5). As soon as MMP-8 is isolated 
from the fusion protein, less intact protein is present in the sample, with only 6% of the total 
protein in the sample being intact MMP-8. Within 10 days the amount of MMP-8 decreases to 
less than 1% intact (Figure 2.5, inset). Not only is the amount of intact fusion MMP-8 eight times 
greater than isolated MMP-8, but approximately 50% of fusion MMP-8 on day 1 remains intact 
after 12 days, while only 15% of MMP-8 on day 1 remains intact on day 10. These results clearly 
	
Figure 2.5 Stability analysis of MMP-8 fusion protein and MMP-8 (Xa-cut) protein separated after Factor 
Xa cleavage. Values were determined using densitometry analysis. Inset is zoomed in bar graph of the isolated 
MMP-8 protein.  
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demonstrate that the fusion tags on MMP-8 have a stabilizing effect and autoproteolysis is 
decreased greatly in the fusion protein compared to MMP-8.  
2.3.6 Activity Assay 
A fluorescent activity assay for MMP-8 was used to examine the activity of the purified 
fusion and isolated Xa-cut MMP-8 (Figure 2.6). The enzyme was examined 1 and 10 days after 
purification and was stored in 50 mM Tris, 60 mM NaCl pH 7.9 with and without (*) 10 µM 
NNGH, an inhibitor predicted to act as a protective stabilizer against proteolysis. Approximately 
100-fold dilution of these protein samples into the assay conditions reduced the inhibitor 
concentration well below the IC50, eliminating its inhibitory effect. After 25 min of incubation 
with the substrate, MMP-8 fusion emits approximately 15,000 RFU on day 1 and day 10. 
Although degradation of the polypeptide chain was observed by SDS-PAGE, the MMP-8 fusion 
	
Figure 2.6 Comparison of catalytic activity in relative fluorescence units (RFU) of the MMP-8 fusion 
protein and its cleaved products as analyzed using MMP-8 Fluorescent Drug Discovery Kit, RED (Enzo 
Life Sciences) at 25 min. Samples were analyzed immediately after purification (day 1) and on day 10. The 
proteins were stored with (day 10) or without (day 10*) a protective stabilizer at 4 °C prior to analysis. Solid 
bars represent the uncut MMP-8 fusion and hashed bars represent isolated MMP-8 following Factor Xa 
cleavage. 
	 56 
retains activity over 10 days both with and without NNGH indicating that addition of this 
compound has no effect. When the fusion tags are removed, MMP-8 appears to lose activity 
compared to MMP-8 fusion when stored without the inhibitor. 
The activity of claMP-link-MMP-8 fusion and Xa-cut protein (MMP-8) were obtained to 
compare to the original MMP-8 fusion and Xa-cut MMP-8 protein lacking the claMP Tag 
(Figure 2.7). MMP-8 fusion was determined to have 3-times higher activity than claMP-link-
MMP-8 fusion when analyzed directly after purification (day 1). Immediately after cleavage with 
Factor Xa, both MMP-8 and claMP-link-MMP-8 retain comparable activity to their original 
fusion construct. Although the claMP Tag and inserted linker decreases the activity of MMP-8 in 
both the fusion and Xa-cut constructs, the extent of diminution is within error. A UV-Vis scan of 
claMP-link-MMP-8 fusion displays all the expected unique spectral features of the Ni-claMP 
complex (data not shown), including the non-overlapping feature at 425 nm to facilitate 
quantitation. Comparison of the A425 value with the total protein concentration, as determined 
by Bradford assay, demonstrated 1:1 binding of the claMP Tag with nickel. The Ni-claMP 
	
Figure 2.7 Comparison of catalytic activity in relative fluorescence units (RFU) of the MMP-8 and claMP-
link-MMP-8 fusion and Xa-cut proteins using MMP-8 Fluorescent Drug Discovery Kit, RED (Enzo Life 
Sciences) at 25 min. Samples were analyzed immediately after purification (day 1). Solid bars represent the 
MMP-8 construct and hashed bars represent the claMP-link-MMP-8 construct. 
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complex is extraordinarily stable and its formation in the fusion construct would preclude the tag 
from interacting with the zinc ion in MMP-8. 
 Because degradation of MMP-8 proceeds quickly once the fusion partner is cleaved, the 
impact on catalytic activity of leaving the fusion partner in the sample to avoid additional 
purification was examined. When the claMP-link-MMP-8 fusion protein was cleaved by Factor 
Xa, it was either separated from the released tag (purified) or was analyzed as a mixture of 
thioredoxin and MMP-8 Xa-cut protein (unpurified). Comparing the two methods of protein 
handling reveals that retention of the fusion partner has an insignificant effect on activity (Figure 
2.8). Previous work has shown that the metal-free claMP module effectively inhibits MMP-8,29 
and new data shows that loading claMP with nickel prevents binding to MMP-8 (manuscript in 
preparation). This data indicates that the claMP Tag may be placed inline with a metalloenzyme 
and when it is loaded with another metal, such as nickel in this study, active enzyme is 
recovered. 
	
Figure 2.8 Comparison of catalytic activity in relative fluorescence units (RFU) of the claMP-link-
MMP-8 fusion and Xa-cut proteins either being purified by SEC after cleavage by Factor Xa or 
not purified, using MMP-8 Fluorescent Drug Discovery Kit, RED (Enzo Life Sciences) at 25 min. 
Samples were analyzed immediately after purification (day 1). Solid bars represent the separated 
claMP-link-MMP-8 construct and hashed bars represent the mixture of cleaved claMP-link-MMP-8 




A fusion construct containing thioredoxin and S Tag N-terminal to MMP-8 resulted in 
the ability to accumulate large amounts of functional enzyme in the soluble fraction of E. coli. 
Subsequent purification using Ni-IMAC and a single SEC step enabled recovery of 20-40 mg of 
MMP-8 from 1 L of cell culture and the purified protein retained full activity at 10 days when 
stored refrigerated at high concentration (~0.5 mM) in a simple buffer solution. The catalytic 
domain of MMP-8 alone is typically stored in 50% glycerol at -80 °C at very low enzyme 
concentration to ensure activity remains, which is not optimal because the presence of glycerol 
can interfere with structural studies and this compound can be difficult to remove. SDS-PAGE 
shows that proteolysis of the fusion protein occurs over the course of several days but this is 
vastly improved compared to MMP-8 alone.  Because the activity remains constant for at least 
10 days, the functional core of the enzyme must remain intact and therefore provides useful 
material for numerous types of analysis, including structural studies where high concentration is 
required.  
Removal of the fusion tags leads to proteolytic degradation and decreased activity. 
Inclusion of the inhibitor NNGH with MMP-8 following Factor Xa cleavage acts as a protective 
stabilizer and improves storage stability of the enzyme. Complete inhibition of MMP-8 is 
accomplished at 7 µM under the conditions of the catalytic assay (MMP-8 Fluorescent Drug 
Discovery Kit, RED (Enzo Life Sciences)), but at the much higher enzyme concentrations 
produced and examined for storage stability herein, 10 µM NNGH was insufficient to prevent 
cleavage of MMP-8 degradation (Figure 2.6).34 Because this concentration is near the limit of 
solubility of NNGH in water, higher concentrations could not be tested. Although NNGH did not 
provide adequate protection against autoproteolysis, the results indicate that identification of 
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inhibitors with higher solubility and/or affinity for the enzyme should improve stability and 
could be used to preserve MMP-8 in the absence of the fusion partner. 
The claMP Tag was added to the MMP-8 construct to examine the effect of an additional 
metal binding entity inline with a metal-containing enzyme. The claMP Tag binds metal 
extraordinarily tightly at basic pH and this fusion system becomes occupied with nickel during 
IMAC purification.30 The metal-free claMP Tag has been shown to inhibit MMP-8 activity and 
is being investigated as a potential regulator of the activity of MMP-8.29 claMP-link-MMP-8 was 
originally designed to contain a linker peptide sequence that would allow the claMP Tag to 
interact with the active site zinc to potentially inhibit the activity of the enzyme as a pro-moiety 
that is releasable by adjusting the pH to below neutral or by inserting another metal into the tag. 
Inclusion of the claMP Tag and linker did not interfere with folding of the enzyme but it did 
impair catalytic function by three-fold. Investigation of the amount of metal bound to the claMP 
Tag determined complete occupancy of the claMP Tag with nickel. The rich UV-Vis spectrum 
of the Ni-claMP complex confirms the claMP Tag is not available to interact with zinc in MMP-
8 and therefore cannot inhibit the enzyme in the fusion construct examined. Although 
demonstrating the reason for this modest decrease in activity is beyond the scope of the present 
study, it is likely that introducing 13 extra residues between the fusion tags and MMP-8 gives 
greater flexibility, allowing for better interaction between the enzyme and the stabilizing partner, 
thereby decreasing activity.  Importantly, like the construct that lacks the claMP Tag, the activity 
remains unchanged with cleavage of the fusion partner (Figure 2.7).    
2.5 CONCLUSION 
Recombinant MMP-8 fusion was expressed and purified using a straightforward 
procedure to obtain active enzyme that is much more stable. The fusion protein can be stored 
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refrigerated in common buffer without glycerol at high concentration and it retains full activity 
for longer than one week. This approach to preparation of MMP-8 is efficient and sufficiently 
simply to enable a wide variety of studies on MMP-8. The claMP Tag may be included in the 
construct and exogenous metal inserted during purification, demonstrating that the inline claMP 
Tag is compatible for use with metalloproteins.  
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CHAPTER 3. METAL-BOUND claMP TAG INHIBITS PROTEOLYTIC CLEAVAGE 
	
3.1 INTRODUCTION 
The specificity provided by a biologic for a target of interest enables delivery of highly 
potent molecules with fewer side effects.1-3 Active pharmaceutical ingredients or chelating 
agents can be conjugated to polypeptides to achieve targeted delivery in therapeutic and 
diagnostic applications. For effective delivery, the intact conjugate must have an adequate 
amount of time to accumulate in the target tissue.4,5 Designing a biologic to remain intact until it 
reaches the target site is difficult because enzymatic degradation processes are capable of rapid 
proteolytic degradation.6-8 Peptides often succumb to short circulation half-lives, either due to 
their small size, being filtered and removed promptly by the kidney, or proteolytic degradation, 
rendering them unable to act at their target site,9-11 such as with the peptide glucagon-like 
peptide-1 (GLP-1) leading to the development of ExenatideTM.12 An appropriate amount of time 
is necessary for the targeting molecule and its payload to reach the target in both therapeutic and 
imaging applications where accumulation at the target site is necessary for effective treatment 
and high-resolution imaging results.13,14 
The half-life of a small biologic is optimized by increasing the time the biologic has to 
reach the target site and is routinely accomplished by chemical modifications that increase size, 
slowing filtration and reducing access by proteases to cleavage sites.15 Synthetic hydrophilic 
polymers such as polyethylene glycol (PEG) increase the circulation half-life and solubility as 
well as decrease proteolysis, demonstrated by PegIntronTM (Schering-Plough).16-18 PEG is a non-
metabolized, synthetic compound. A better tolerated and biodegradable partner is desirable.6,19 
Genetic incorporation of an amino acid polymer, known as XTEN, consisting of a sequence of 
hydrophilic, stable residues creates an inline, homogeneous half-life enhanced molecule.20 Used 
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as an alternative to PEG, XTEN is practical to encode biosynthetically and, while resistant to 
serum proteases, is biodegradable.21 Conjugation of 288 amino acids of XTEN to the hormone 
glucagon (Gcg) increased the half-life from 10 min to 9 h22 and XTEN addition to both termini 
of recombinant human growth hormone (rhGH) to produce Somavaratan (VRS-317) yields a 30-
60-fold increase in plasma half-life, potentially enabling once monthly dosing instead of daily 
injection.23 Increasing half-life by enlarging size, however, results in longer exposure time to 
proteases. Resistance to proteases through strategic engineering is important for combating loss 
through enzymatic degradation. While amino acid tags used to increase the serum stability of 
peptides are being developed, none have been consistently reliable. Thus, a method to inhibit 
proteases across a broad range of peptides is still sought.24 
The need to extend the half-life of peptides is particularly important when they are used 
as imaging agents.15,25 Peptides conjugated to a chelator generate contrast agents for imaging 
applications to visualize tumors for diagnosis. For example, SandostatinTM (Novartis 
Pharmaceuticals), a somatostatin analog, has an improved half-life of somatostatin from 2 min to 
90 min and when radiolabeled creates a conjugate capable of effectively imaging carcinoid 
tumors.26 In applications involving metals, circulating half-life is typically short because dilution 
into the large volume of a patient leads to rapid loss of the metal from the carrier via 
transmetallation reactions.27,28 When metal is lost from the chelator prematurely, free metal ions 
accumulate in the bone and liver causing changes to normal cellular processes, toxicity and 
elevated background signal, decreasing the quality of the image.29-32 Lanthanides are used 
currently because available chelators are poorly compatible with small transition metals, but 
small transition metals are preferred because of their biocompatibility and decreased patient 
toxicity.33,34 An alternative method for delivery of metals to a target site for imaging is to use the 
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novel metal-binding tripeptide known as the claMP Tag.35-37 The claMP Tag has the capability 
of acting as a contrast agent by binding safe, biocompatible transition metals rather than large, 
toxic lanthanide ions. Our lab discovered the unique metal abstraction peptide (MAP) chemistry 
and developed the inline claMP Tag, which is currently being investigated as a targeted delivery 
method of transition metals for therapeutic and diagnostic applications. The tag consists of the 
amino acid sequence Asn-Cys-Cys and binds transition metals extraordinarily tightly,38-40 
making it possible to increase effective circulation time and target-specific tissue accumulation 
for transition metal-based imaging agents. The metal-claMP complex has been shown to not 
disrupt the overall protein structure, including proteins that depend on formation of multiple, 
complex disulfide bonds for proper folding and function.38,41 To investigate susceptibility of the 
metal-bound claMP Tag to proteolytic cleavage and determine viability of using this tag in 
targeted imaging applications, an in-vitro proof of concept study of a fusion protein was carried 
out by engineering the claMP Tag adjacent to a known recognition site for the serum protease 
Factor Xa. A series of spacer residues was added between the protease binding motif and the tag 
to further examine the ability of the claMP Tag to affect cleavage at the recognition site.  
3.2 MATERIALS AND METHODS 
3.2.1 Genetic Engineering   
Six constructs of claMP-maltose binding protein (MBP) were prepared. Five of the DNA 
sequences contained the claMP Tag (NCC) each with an increasing number of glycine residues 
on the N-terminus, from zero to four. In addition, a control was generated in which cysteine 
residues were replaced by alanine to eliminate metal binding. To create the recombinant DNA, a 
plasmid containing MBP in the pMAL-C5X vector was obtained (New England Biolabs, Inc.) 
and the MBP sequence was amplified with the different N-terminal primers (Integrated DNA 
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Technologies) using PCR. The primers consisted of a region matching the pET-32Xa/LIC vector 
shown as underlined, followed by the glycine spacers and claMP Tag sequence, and lastly a 
portion matching the N-terminal MBP sequence shown in bold (Gly4, 5’-ATT GAG GGT CGC 
GGA GGA GGA GGA AAC TGT TGT GGC AAA ATC GAA GAA-3’; Gly3, 5’-GGT ATT 
GAG GGT CGC GGA GGA GGA AAC TGT TGT GGC AAA ATC GAA GAA-3’; Gly2, 5’-
GGT ATT GAG GGT CGC GGA GGA AAC TGT TGT GGC AAA ATC GAA GAA GG-3’; 
Gly1, 5’-GGT ATT GAG GGT CGC GGA AAC TGT TGT GGC AAA ATC GAA GAA GG-
3’; Gly0, 5’-GGT ATT GAG GGT CGC AAC TGT TGT GGC AAA ATC GAA GAA GG-3’; 
Control, 5’-GGT ATT GAG GGT CGC AAC GCA GCA GGC AAA ATC GAA GAA GG-3’) 
The PCR reactions were purified using the QIAquick PCR Purification Kit (Qiagen) and the 
resulting product was inserted into the pET-32Xa/LIC vector via procedure provided by the 
manufacturer (Novagen). The ligation independent cloning reaction was then transformed into 
the DH5α Escherichia coli (E. coli) cell strain using the standard heat shock procedure. The cells 
were plated on LB agar plates with 100 µg/mL ampicillin and incubated overnight at 37 °C. 
Colonies were individually grown in 5 mL of LB with 100 µg/mL ampicillin overnight at 37 °C, 
250 rpm. Cells were pelleted at 4000 rpm for 15 min and the supernatant discarded. The DNA 
was harvested using a miniprep kit (Qiagen) and confirmed by DNA sequencing (UC Berkeley 
DNA Sequencing Facility). 
3.2.2 Protein Expression 
Plasmids were transformed into BL21 E. coli using the standard heat shock technique. 
The cells were plated on LB agar plates with 100 µg/mL ampicillin and incubated overnight at 
37 °C. Starter cultures were prepared using a single colony to inoculate 50 mL of LB with 100 
µg/mL ampicillin and grown for 16 h at 37 °C, 250 rpm. Twenty milliliters of starter culture 
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were used to inoculate 1 L of LB with 100 µg/mL ampicillin in a 3-L Fernbach flask. The cells 
were grown at 37 °C, 250 rpm until the OD600 reached approximately 0.7 and expression was 
induced by addition of 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG). The cells were 
cultured for 4 h more and then harvested by centrifugation. Cell pellets were stored at -80 °C 
until use. 
3.2.3 Protein Purification 
Each 1 L pellet was resuspended in 25 mL of freshly made 50 mM Tris-Cl, 200 mM 
NaCl, pH 7.4 and lysed by three passes through a French press at 21,000 psi. The lysed cells 
were centrifuged for 1 h at 21,000 x g and 4 °C. The supernatant containing the protein was 
filtered through a 1.2 µm filter and applied to a nickelated 5 mL Hi-Trap Chelating HP column 
(GE Lifesciences). The column was washed with 50 mM Tris-Cl, 200 mM NaCl, 40 mM 
imidazole, pH 7.4 for 20 CV at a flow rate of 1.25 mL/min at 4 °C. The protein was eluted with 
25 mL of 50 mM Tris-Cl, 200 mM NaCl, 250 mM imidazole, pH 7.4. Samples were diluted to 
100 mL with 50 mM Tris-Cl, 100 mM NaCl, pH 8. The eluent was applied to a 10-mL column of 
amylose resin (New England Biolabs, Inc.) at 1.5 mL/min using an Econo Pump (BioRad) and 
MBP proteins were eluted with 40 mL of 50 mM Tris-Cl, 100 mM NaCl, 10 mM Maltose, pH 8. 
The protein was concentrated using Amicon Ultra 30 kDa MWCO concentrators (Millipore) to a 
final concentration of approximately 0.5-1 mM. 
3.2.4 Nickel Release 
Metal was released from the claMP Tag by decreasing the pH and incubating with 
EDTA. Approximately 1 mL of metal-bound protein was diluted to a final concentration of 10 
mM EDTA, 12 mM succinate, 35 mM citrate and 70 mM NaCl, pH 6.8. This diluted the amount 
of maltose in the sample to approximately 0.2 mM. Protein was incubated at room temperature 
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for approximately 2 h and either concentrated to 0.5 mM for metal quantification using 
absorption spectroscopy or applied to amylose resin and eluted with 30 mL of 50 mM citrate, 
100 mM NaCl, 10 mM maltose, pH 6.5.  
3.2.5 Factor Xa Cleavage 
Constructs were prepared in 500 µL aliquots of 0.05 mM. Factor Xa (Novagen, 0.98 
mg/mL) was added to a final concentration of 0.3 nM. The reaction was carried out at room 
temperature and monitored for up to 12 h.  
3.2.6 SDS PAGE Analysis 
Thirty microliter aliquots of 0.05 mM protein were collected at 0, 1, 2, 4, 6, 8, 10, and 12 
h, combined with 30 µL of reducing Laemmli buffer and heated at 90 °C for 10 min. Samples 
were stored at -20 °C until used. Two microliters of each gel sample were loaded onto standard 
15% (v/v) resolving, 4% (v/v) stacking gels and run at 135 V for 4 h. A pre-stained molecular 
weight ladder was used as a reference (BioRad, #161-0374). Gels were stained with SYPRO 
Ruby Protein Gel Stain (Life Technologies, cat# S-12000) according to the manufacturer’s 
instructions. Replicates were obtained by adding Factor Xa to three individual aliquots of protein 
at a concentration of 0.05 mM protein. Samples of equivalent volumes of protein were added to 
reducing or non-reducing laemmli buffer at each time point. SDS-PAGE was completed for each 
of the three replicates for each protein construct. 
3.2.7 Densitometry Analysis 
The analysis was performed using a Typhoon TRIO Variable Mode Imager (Amersham 
Biosciences) and ImageQuantTL software (Amersham Biosciences). Relative intensity values in 
RFU were measured for each band and normalized to 100% for each lane in order to eliminate 
gel-loading variability between samples. The replicates at each time point were averaged and the 
	 71 
time 0 point, before Factor Xa was added, was normalized to 100% intact protein. The intact 
fusion protein was quantified in each lane of the gel and the relative amount cleaved was 
determined compared to the time 0 point. Plots of the relative normalized natural log of the 
relative fluorescent units (RFU) over time 
displayed a nearly linear relationship with 
R2 values displayed in Table 3.1. The 
relative cleavage rate was determined from 
the slope and the error analysis displays a 
90% confidence interval. 
Secondary cleavage at the thrombin 
recognition site was observed. The relative 
amount of protein cleaved at the Factor Xa 
recognition site was quantified as a percentage compared to the total to account for only cleavage 
at the site adjacent to the claMP Tag and not the minor non-specific cleavage site.  
3.3 RESULTS 
3.3.1 SDS-PAGE and Densitometry Analysis to Quantify Proteolytic Cleavage 
In previous studies of claMP-Tagged proteins embedded in cleavable fusion constructs, 
inclusion of the metal-bound tag slowed the ability to cleave the fusion partner.38 Therefore, this 
in vitro proof of concept study was initiated to examine how the proximity of the claMP Tag to a 
protease recognition site affects cleavage by a serum protease. The claMP Tag was genetically 
engineered into a fusion protein (Trx-claMP-MBP) adjacent to the serine protease Factor Xa 
recognition site between thioredoxin (Trx) and maltose binding protein (MBP) (Figure 3.1A), 
and the extent to which the metal-bound claMP Tag inhibits the ability of Factor Xa to cleave at 







Gly4 0.97 0.98 
Gly3 0.95 0.99 
Gly2 0.96 0.98 
Gly1 0.95 0.97 
Gly0 0.92 0.99 
Control 0.98 0.98 
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the adjacent site was examined. Five variants of Trx-claMP-MBP were made to examine the 
effect of changing the spacing between the enzymatic recognition site and the claMP Tag. Zero, 
one, two, three or four glycine residues were engineered between the cleavage site and the 
claMP Tag (Figure 3.1B and C). A non-metal binding control (NAA) also was made in which 
the two Cys in the claMP Tag were substituted with Ala. At basic pH metal is bound to the tag, 
kinking the protein next to the recognition site, but in acidic conditions metal is released.  
SDS-PAGE was used to observe protein cleavage as a function of time and densitometry 
analysis was performed for quantification. The 58-kDa fusion protein is cleaved after the 
intended Factor Xa recognition site (Ile-Glu-Gly-Arg) into two fragments of 41 kDa (claMP-
	
Figure 3.1 Depiction of the proof of concept study used to understand the inhibitory nature of the claMP 
Tag.  (A) Cartoon of the fusion construct illustrating the inhibitory effect of the Ni-claMP complex on Factor 
Xa cleavage. (B) Five of the constructs (three shown) consist of the claMP Tag with a varied number of glycine 
spacers (1-3). A control without the two-cysteine residues (NAA) responsible for binding nickel was also tested 
(4). Ni2+ is represented by a green circle, which is bound by the claMP Tag (red). The blue box illustrates the 
spacer positioned between the Factor Xa recognition site (black line) and claMP Tag. (C) Abbreviated names 
for each of the six protein constructs. 
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MBP) and 17 kDa (Trx) (Figure 3.2), as verified by ESI-MS. The decrease in the amount of 
intact fusion protein (58 kDa) over time was quantified. A linear fit was established by plotting 
the relative normalized natural log of the relative fluorescence units (RFUs) acquired using 
densitometry vs. time (Figure 3.3).  
	
Figure 3.3 Plot of relative cleavage of Ni-claMP Tag constructs demonstrating the inhibitory action of 
the inline metal-bound claMP Tag. The control, followed by Ni-Gly0 have the fastest cleavage rates as 
shown by the first order relative rate plot. Error bars reflect a 90% confidence interval with n=3 data points. 
The R2 values range from 0.92 to 0.99 indicating the majority of the constructs do not fit precisely to a first 
order linear function (Table 3.1).   
	
	
Figure 3.2 Factor Xa cleavage of the fusion protein, Trx-claMP-MBP, over a 24-hour incubation 
period. Trx-claMP-MBP is cleaved at the Factor Xa recognition site into two fragments, claMP-MBP (41 
kDa) and Trx (17 kDa). Trx is not shown because it is too small to be retained on the gel. The gels were 
stained with SYPRO Ruby Protein Gel Stain, which only allowed visualization of the 75-kDa molecular 
weight marker. The gel was aligned with the marker set by Coomassie staining and the ladder is shown.  
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3.3.2 The Metal-bound claMP Tag Inhibits Proteolysis 
Ni-Gly1 was determined to inhibit Factor Xa by approximately 3-fold compared to the 
control at the 12-hr time point showing the most inhibition compared to the other five constructs 
(Figure 3.4). At the 12-hr time point Factor Xa cleaved 28% of the Ni-Gly1 construct whereas 
83% of the control was cleaved. If Ni-
claMP occludes access to the site based on 
steric hindrance, it would follow that the 
rate of cleavage would be slowest with the 
shortest spacer Ni-Gly0 and faster with the 
longest spacer Ni-Gly4. This trend was 
observed generally among the constructs 
examined except for one outlier, Ni-Gly0. 
Starting with Ni-Gly1, the trend held true; 
Ni-Gly1 had the slowest cleavage rate and 
increasing the number of glycine residues in 
the spacer led to increasing cleavage rate 
with Ni-Gly3 and Ni-Gly4 having approximately the same rate. At 12 h, 28% of Ni-Gly1, 36% 
of Ni-Gly2, 51% of Ni-Gly3, and 48% of Ni-Gly4 were cleaved (Figure 3.4). Surprisingly, 
Factor Xa cleaved similar amounts of Ni-Gly0 (54%) and Ni-Gly4 (48%). Ni-Gly0 displayed a 
slower rate of cleavage than the control, suggesting the claMP module does impede access to the 
cleavage site, but this construct’s deviation from the trend was unexpected because the protease 
recognition site directly abuts the Ni-claMP Tag and would be expected to more effectively 
hinder approach by the enzyme than the Ni-Gly1 and Ni-Gly2 variants.	 
	
Figure 3.4 The Ni-claMP Tag inhibits proteolysis relative 
to the control for all five constructs depicted at the 12-hr 
time point. Ni-Gly1 exhibits the most inhibition with a 3-
fold decrease in proteolysis compared to the control. Error 




3.3.3 Partial Metal Release Increases Proteolysis  
To understand how metal bound to the claMP Tag impacts proteolysis compared to the 
empty claMP Tag sequence, the six constructs were subjected to mild acidic conditions in the 
presence of a chelating agent to release nickel form the claMP Tag and incubated with Factor 
Xa. The Ni-claMP Tag has spectral features in the UV and visible regions representing the 
unique structure of the metal-bound tag with identified peak maxima at 418 nm and 530 nm 
(Figure 3.5).37,38 As such, UV-Vis 
absorption spectroscopy was used to 
quantify the metal remaining bound to 
the claMP Tag. An extensive screen 
of conditions and approaches was 
performed to identify a set of 
parameters under which comparable 
and consistent results could be 
achieved, culminating in the 
conditions reported herein. All 
variants shown in Figure 3.5 were 
analyzed at equivalent protein 
concentration, highlighting the absorption difference when metal is bound. The absorption 
differences between the three constructs in the UV region are due to the Ni-bound claMP Tag 
absorption at 313 nm.37 The control protein that does not contain the claMP Tag has no 
absorbance in the visible region and also lacks the ligand to metal charge transfer band at 313 nm 
indicative of the metal-bound state, whereas these distinct features are observed with both fully 
	
Figure 3.5 Nickel is incorporated and released from 
constructs containing the claMP Tag. The distinct features in 
the visible region indicate the unique structure of the metal-bound 
claMP Tag. Ni-Gly1 is fully occupied and Gly1 is the partially 
occupied claMP Tag after incubation at low pH with a chelator. 
The control does not contain the claMP Tag and shows no 
absorbance in the visible region. 
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occupied Ni-Gly1 and partially occupied Gly1, but in different proportions relative to the protein 
absorbance at 280 nm (Figure 3.5). 
Results of the absorption spectroscopy revealed that metal is not released fully nor at 
equivalent rates and varies among the set of constructs analyzed. Consequently, it was necessary 
to quantify the percentage of metal retained in the claMP Tag to compare the extent of cleavage 
by Factor Xa among the constructs (Table 3.2). Metal quantification became increasingly 
problematic with longer incubation at pH 6.5 due to instability of the samples, which resulted in 
light scattering, precipitation and protein loss from solution.  The amount of metal released after 
incubation at pH 6.5 with EDTA for 2 h was determined to be the most consistently reliable time 
point for measuring metal release without interference and ranged from 46.6% to 69.4%. Most 
constructs released more than 57% of the nickel from the claMP Tag, but Gly0 again was an 
outlier displaying greater retention of metal with only 46.6% released. Subsequent Factor Xa 
cleavage of the constructs demonstrates Gly1 is the most inhibitory, reducing cleavage more than 
2-fold compared to the control. Gly2 and Gly3 have less impact on cleavage as additional Gly 






























Gly1 33 ± 1 43 ± 6 43 ± 6 0.33 1.0 3.0 
Gly2 43 ± 2 70 ± 10 37 ± 2 0.43 1.8 4.2 
Gly3 61 ± 2 82 ± 3 31 ± 4 0.61 2.7 4.4 
Gly4 58 ± 3 68 ± 2 43 ± 2 0.58 1.6 2.7 
Gly0 65 ± 4 91.3 ± 0.5 50 ± 10 0.65 1.7 2.6 
Control 100 ± 3 100 ± 5 N/A 1.0 1.0 1.0 
aPercent protein cleaved normalized to the control at pH 8. bPercent protein cleaved normalized to the control at pH 
6.5. cPercent metal retained in the claMP Tag after incubation at pH 6.5 with EDTA for 2 h (n=2). dRelative ratio of 
percent protein cleaved to percent metal bound at pH 8, where the percent protein cleaved is divided by 100% 
metal-bound. eRelative ratio of percent protein cleaved to percent metal bound at pH 6.5. fComparison of pH 6.5 to 
pH 8 of the ratios of percent protein cleaved to % metal bound. Error represents standard deviation of n=2 or 3.  
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residues are placed between the enzymatic recognition sequence and the claMP Tag. In general, 
the percentage of apo-claMP Tag and percentage of protein cleaved increased as the number of 
glycine spacers was increased, with the exception of Gly0 (Figure 3.6). Gly0 is clearly an 
exception; this construct released appreciably less of the nickel than other constructs and yet had 
the greatest percentage of proteolysis. This result, however, does make sense because cleavage 
occurs more rapidly when metal is bound to this construct compared to the others. The data set 
generally suggests the metal-bound claMP Tag hinders access by the enzyme to the cleavage 
site, presumably because of its bulky, kinked structure. Clearly with Gly0 proteolysis is not 
dependent solely on metal-binding to the claMP Tag because it deviates from the trend of 
increased proteolysis with increased number of Gly spacer residues. The study shows that 
cleavage by Factor Xa is dependent on the presence of the claMP Tag, its proximity to the 
hydrolyzed peptide bond and metal occupancy of the tag. On average, the partially metal 
occupied claMP Tag inhibited proteolysis approximately 2-fold, and the fully occupied Ni-
claMP Tag displayed a 3-fold increase in inhibition, leading to the conclusion that the 
engineered sequence alone may modulate proteolysis and metal binding to the claMP Tag further 
impedes cleavage.  
The six constructs with partial metal release were compared to the nickel-bound 
constructs that were cleaved at pH 8. Because the rate of cleavage by Factor Xa differs between 
pH 6.5 and 8.0,42 the relative results are compared by normalizing cleavage of the control protein 
at each pH to 100%. A similar trend to the fully metal-bound data set was observed (Figure 
3.6A), where Gly1 exhibited the greatest inhibition, followed by Gly2, Gly3 and Gly4. In each 
case, a greater amount of cleavage was observed at pH 6.5 where metal release from the claMP 
Tag occurs. The Gly0 construct, which had 54% cleaved at pH 8, demonstrates that proteolytic 
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susceptibility can be restored upon metal release, as evidenced by a similar amount of cleavage 
as the control, with 91% cleaved at 12 h (Figure 3.6A). In other samples subjected to conditions 
of metal release, substantial variability in the amount of protein cleaved was observed for the 
constructs with more Gly spacers, leading us to suspect differing degrees of instability or metal-
release from these molecules, possibly via metal-based crosslinking because non-reducing SDS-
PAGE shows insignificant formation of intermolecular disulfide bonds between cysteine residues 
in the tag sequence following metal release (data not shown). Because a truly quantitative 
analysis of the metal-free proteins and comparison to their Ni-bound analogs would require 
larger amounts of pure metal-free starting materials and detailed characterization of differences 
in chemical and physical stability among the constructs, particularly with respect to the oxidation 
state of cysteine residues from the tag, herein we first demonstrate that the claMP Tag inhibits 
proteolysis by a serum protease, indicating subsequent more in-depth studies are warranted.  
Because the metal is only partially released and to differing extents among the constructs 
	
Figure 3.6 Relative cleavage of constructs at pH 6.5 compared to pH 8. (A) The claMP Tag at pH 6.5 shows 
that metal release increases cleavage relative to the fully metal-bound analog at pH 8 and the control, but that 
cleavage remains below the level of the pH 6.5 control. Histogram represents the relative percent cleaved at 12 h 
normalized to the control at the same pH. Error bars reflect a 90% confidence interval with n=3 data points. (B) 
Comparison of cleavage relative to the amount of metal bound to the claMP Tag. The ratios show that a substantial 
increase in cleavage occurs when metal is released. 
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and recovery of metal-free protein is poor, presumably due to instability, and in addition the 
enzyme cleavage rate slows as a function of time due to product formation, accurate quantitation 
of cleavage rate for the constructs was not feasible. As such, quantitative values reported herein 
are intended solely for the purpose of demonstrating relative comparisons and trends. Both the 
metal-bound and apo claMP Tag constructs demonstrate a decrease in proteolytic cleavage as the 
spacer length is reduced from four to one glycine (Gly4 to Gly1) and that elimination of a spacer 
residue partially abrogates the inhibitory effect. The sequence, Gly1 was determined to be the 
most effective inhibitor of Factor Xa, decreasing cleavage rate by approximately 3-fold 
compared to the control. The tabulated results at pH 8 reveal a large reduction in the amount of 
protein cleaved compared to control when metal is bound to the claMP Tag (100% occupancy), 
whereas at pH 6.5, which is amenable to metal release, substantially more protein is cleaved in 
the same amount of time. Within each condition, the percent protein cleaved increases from Gly1 
to Gly4, indicating more protein is cleaved with an increasing number of glycine residues at both 
pH 8 and pH 6.5. The values presented in Table 3.2 are relative (normalized to percent of 
control) and the ratios also are reported proportional to the amount of metal bound to permit 
comparison of results at the two different pH conditions. Taking the ratio of the amount of 
protein cleaved relative to the amount of metal bound with each construct at pH 6.5 to pH 8, it is 
clear substantially more protein is cleaved at pH 6.5 than pH 8 due to metal release (Figure 
3.6B). The higher the ratio the greater the amount of protein cleaved at pH 6.5, when the protein 
is metal free, than at pH 8. 
3.4 DISCUSSION 
In previous studies, it was determined that the MAP chemistry is compatible with 
recombinant production of difficult to express proteins having intramolecular disulfide bonds 
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because the engineered claMP Tag does not interfere with proper folding and protein 
structure.38,39 In the preparation of proteins used in these studies, however, slow or incomplete 
cleavage of the fusion partners was observed for some constructs. Here, an in vitro proof of 
concept study was performed to examine how the proximity of the claMP Tag to a protease 
recognition site affects cleavage at the known recognition site by the serum protease Factor Xa 
embedded in a thioredoxin (Trx) - maltose binding protein (MBP) fusion protein as a model 
system. The nickel-bound claMP complex has been extensively characterized, and therefore, 
nickel was inserted into the claMP Tag in this investigation because this metal complex has 
extraordinary stability and its rich spectroscopic properties enable quantitative analysis of metal 
incorporation.38,39 Nickel is a suitable substitute for other transition metals such as platinum and 
copper (unpublished data), which are sought after elements for therapeutic and diagnostic use.  
When metal is bound to the tag, there is a 3-fold decrease in cleavage rate compared to 
the control protein. Figure 3.7 depicts how the metal-bound claMP Tag alters the protein’s 
conformation and flexibility to inhibit proteolysis. When metal is not bound to the claMP Tag, 
the conformation of the tripeptide sequence and therefore the orientation of the two fusion 
proteins with respect to each other, is less restricted. In comparison, when the claMP Tag is 
occupied with metal, the tag becomes constrained by the obligate square planar geometry of the 
coordinating moieties and access to the adjacent recognition site by Factor Xa is altered, 
decreasing the ability to cleave the protein. In the metal-bound state, the protein sequence bends 
around the metal ion forming a tight turn, kinking the protein. Additional glycine residues were 
included in an effort to increase flexibility adjacent to the recognition site and to increase space 
between the tag and cleavage site, allowing the enzyme greater ability to approach and cleave the 
protein.  
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Based on the structures presented in Figure 3.7, Ni-Gly0 would be expected to have the 
slowest rate of cleavage if dominated by steric hindrance and the rate would increase as a larger 
number of glycine residues were placed between the enzyme recognition sequence and the 
claMP Tag as a spacer. The trend of increasing cleavage rate with increasing number of spacer 
residues was observed for the constructs assembled with glycine spacers, with the exception of 
Gly0, which surprisingly has a more rapid rate of cleavage than Gly1-4, indicating that the 
amount of space is not the only significant influence on cleavage rate. It was expected that metal 
insertion would affect the structure between the two folded domains, causing the fusion protein 
to adopt a more protease-resistant conformation when the claMP Tag is loaded, as observed for 
constructs with 1-4 Gly spacer residues. Because the relative cleavage rate of Gly0 deviates from 
the expected trend, it is evident that in addition to steric hindrance adjacent or neighboring 
residues influence the rate of hydrolysis.43,44 This construct may have a conformation that is 
preferred by the enzyme, while those with spacer residues are more resistant to proteolysis. 
However, a notable chemical difference is that Gly0 has metal bound directly to the nitrogen of 
the peptide bond that is cleaved by the enzyme, and it is reasonable to anticipate direct metal 
	
Figure 3.7 Chemical structures indicating the site of hydrolysis by Factor Xa. Arginine is the final residue of 
the Factor Xa recognition site and adjacent is the claMP Tag (Asn-Cys-Cys). Red arrows and bonds represent the 
site of peptide bond hydrolysis by Factor Xa. The claMP Tag (a) without metal-bound (Gly0), (b) with metal (Ni-
Gly0), and (c) with metal-bound and one glycine residue (Ni-Gly1). 
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coordination by the amide nitrogen of the cleaved peptide bond may promote hydrolysis (Figure 
3.7b). Metal ions have chemical reactivity and can cause peptide bond breakage either through 
oxidation or hydrolysis.45,46 Copper (II) binding within the hinge region of IgG1 monoclonal 
antibodies (mAbs) can lead to fragmentation, and in some cases, neighboring residues have been 
shown to alter the rate of hydrolysis of the peptide bond adjacent to the metal binding site.47 
Nickel and other cationic transition metals are Lewis acids with high electron affinity, causing 
bond polarization and facilitating hydrolysis as well.48 Metals also can promote hydrolysis by 
activating a water molecule that can be deprotonated by an adjacent basic side chain, mimicking 
natural metalloproteinases that use metals in their active site for the purpose of proteolytic 
hydrolysis.49,50 Importantly, because the nickel-bound claMP Tag and fusion protein is stable in 
the absence of Factor Xa, the presence of metal alone does not account for the observed increase 
in cleavage of the Gly0 construct. It is more likely that displacement of the proton from the 
backbone amide nitrogen by Ni(II) in the claMP Tag complex accelerates cleavage by altering 
the electronic properties of this peptide bond, making the enzymatic reaction more favorable. 
This could be accomplished by a preferred orientation that permits greater access to the 
recognition site or through the provision of a chemical moiety that facilitates the reaction or a 
combination of both. Because the adjacent residue is Gly in all of the constructs examined, the 
result is likely because another nearby residue in this construct presents a functional group in a 
structurally favorable position to facilitate more effectively the hydrolytic reaction. Although 
hydrolysis of the Gly0 construct occurs faster than the other claMP Tag constructs, Gly0 still 
offers significant protection compared to the control, indicating that inclusion of the metal-bound 
claMP Tag inhibits proteolysis and that the construct’s stability can be tuned by placement and 
composition of neighboring residues. 
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In order for Factor Xa to attack the carbonyl of the stable amide bond in the peptide 
backbone of the substrate, residues within the substrate pocket of Factor Xa act as a general acid 
by hydrogen bonding to the carbonyl of the substrate, creating a more electrophilic carbon center 
for nucleophilic attack.51,52 Metal bound adjacent to the hydrolyzing peptide bond will increase 
the electron withdrawing effects, resulting in a more electrophilic center for nucleophilic attack 
by the serine residue, increasing the rate of peptide bond cleavage compared to when metal is not 
bound adjacently. This explanation would account for the anomalously fast rate of cleavage for 
Gly0, while steric occlusion explains the overall trend among the series of Gly-containing 
constructs with protonated rather than metal-bound adjacent nitrogen atoms. Once the kinked Ni-
claMP Tag and the folded domains of the fusion partners are sufficiently separated in space from 
the protease recognition site, cleavage rates are expected to become more similar as more glycine 
residues are added. The rates of cleavage of Gly3 and Gly4 with and without metal are 
statistically equivalent. This result suggests that the metal-bound claMP Tag is directly 
responsible for inhibition when fewer than three residues separate the tag from the recognition 
site. Although a much larger series of variants would need to be examined to verify the 
mechanism, when three or more spacer residues are present, it seems that the size of the folded 
domains instead may limit diffusional access to the binding site to restrict approach by the 
enzyme.  
Control of proteolysis is crucial and knowing both where and when cleavage occurs 
enables design of effective therapeutics. Prodrugs and antibody drug conjugates (ADCs) are 
designed to use proteolysis to their advantage. Such biologics aim to be stable and inaccessible to 
proteases in the serum yet degraded through proteolytic cleavage in the lysosomal compartment 
of the target cell to release the payload.53,54 The activity of Factor Xa was examined to gain an 
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initial understanding of the inhibitory action of the claMP Tag when exposed to a serum 
protease, but during conditions of stress, such as disease, protease activity can increase. Disease 
states, specifically tumor metastasis, are typically associated with upregulation of proteases, 
which is the main concern when protection is needed until the biologic is internalized into the 
target cell.55,56 It is particularly important for ADCs to contain a stable linker to avoid proteolysis 
and release of the conjugated toxin before reaching the target because they can be in circulation 
for days.57,58 The site of release of the toxin will impact the toxicity profile and premature, 
untargeted release may cause unwanted toxicity.59-61 The ability to slow proteolysis in the serum 
by 3-fold or more would provide significant protection against premature release. As 
demonstrated in this proof of concept study, inclusion of the metal-bound claMP Tag can protect 
proteins from proteolytic degradation and by inference should decrease side effects due to 
premature release of a toxic payload in serum. ADCs target extracellular receptors and are taken 
up via endocytosis.62 A commonly employed ADC delivery approach relies on enzymatic release 
of the toxic payload in lysosomes by cathepsin B.63 pH decreases with endocytosis and the acidic 
environment facilitates enzymatic cleavage. The claMP Tag has been demonstrated to be both 
stable and protease resistant in mildly basic conditions, including those that emulate serum.41 
Importantly, metal release from the claMP Tag occurs solely below pH 7.00 in acidic 
conditions40 such that once a targeted molecule is directed to the lysosome62, cleavage would not 
be impeded because the tag would empty concomitantly. For practical reasons of analysis pH 8 
was chosen for this study instead of serum pH with knowledge that the structure of the Ni-claMP 
complex remains unaltered above neutral pH up to at least pH 9.40 Although actual enzyme rates 
of cleavage differ with pH, relative differences in cleavage of the constructs at pH 8.0 and 7.4 
are expected to be similar and to follow the same trends. Previous stability characterization at pH 
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7.3 of claMP-Tagged protein showed the complex remains stable for at least 12 weeks.39 
Examining proteolysis at a mildly basic pH where metal is retained and at acidic pH where metal 
is released allowed initial comparison of proteolysis among a series of claMP-Tagged constructs 
within a simple system. Once a clinical candidate is identified, further experiments in serum 
would enable identification of all fragments and cleavage sites relevant for in vivo degradation.  
Although all constructs with the metal-bound claMP Tag slowed proteolysis, it is evident 
that the specific amino acid sequence surrounding the tag affects cleavage. Further exploration of 
the adjacent sequence, specifically substitution of the glycine residues to more bulky groups, 
should be pursued to determine to what extent residue choice in neighboring positions offers 
greater protection. The presented data demonstrate clearly the claMP Tag reduces proteolysis at 
an existing recognition site. The claMP Tag not only provides protection from unwanted 
degradation, but this finding provides support for its use for the targeted delivery of metals. As 
such, further exploration of the amino acid residues surrounding the claMP Tag is warranted to 
determine the optimal sequence for resisting cleavage by Factor Xa and other serum proteases. 
3.5 SUPPLEMENTAL DATA 
3.5.1 Probing the Amino Acid Sequence Surrounding the claMP Tag 
 The amino acid sequence surrounding the claMP was varied to identify residues that are 
able to improve inhibition. Either the Asn residue of the claMP Tag within Ni-Gly0 or the Gly 
residue preceding the claMP Tag within Ni-Gly1 were mutated to different residues 
(Supplementary Figure 3.1). Asn was mutated to either Gly or Val and both Gly and Val 
improved inhibition by 1.8-fold compared to Ni-Gly0 (Supplementary Figure 3.1a). The Gly 
residue preceding the claMP Tag was changed to either Pro, Arg, Lys, Val, Phe, or Thr within 
Ni-Gly. Other than Pro, Gly was determined to be the most inhibitory compared to the other five 
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mutations (Supplementary Figure 3.1b). Pro is known to inhibit Factor Xa, so this inhibition is 
not due to the claMP Tag, but is due to the proline residue itself.64  
Supplementary Figure 3.1 Varying the amino acid sequence surrounding the metal-binding site of the claMP 
Tag showed small improvements in proteolytic stability. (a) Mutation of Asn residue within Ni-Gly0 showed 
small improvement in proteolytic stability. (b) Mutation of Gly residue within Ni-Gly1 and the only improvement in 
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CHAPTER 4. DESIGN AND CHARACTERIZATION OF A claMP-TAGGED EGFR 




 Non-invasive imaging techniques provide means of visualizing biological processes to 
aid in early diagnosis and treatment, ultimately improving patient prognosis.1-4 Targeted 
molecular imaging probes consist of a targeting molecule, such as a peptide, protein, or antibody, 
conjugated to a chelator. These molecular probes are coupled with imaging techniques, such as 
positron emission tomography (PET) and single-photon emission computed tomography 
(SPECT) to provide functional information and enable quantification of disease-related 
biochemical processes, adding more detail to currently used anatomical techniques such as MRI 
and CT.5,6 Aspects such as ligand affinity, ligand properties (molecular weight, lipophilicity and 
charge), tissue uptake, and background signal must be considered in designing a molecular 
probe.7 Stability in the systemic circulation is necessary for the molecule to reach the target 
tissue and accumulate in it, while rapid clearance from sites that do not contain the target is 
necessary to achieve high contrast images.8 Often, molecular probes are specifically designed 
with a half-life that achieves these desired pharmacokinetic properties. For example, Octreotide 
was designed as a proteolytic-resistant prototype of the native somatostatin hormone that has a 
half-life of only 3 min caused by enzymatic degradation.9 Incorporation of unnatural amino acids 
and disulfide crosslinking increased the half-life to approximately 100 min,10 and rapid tumor 
uptake and background clearance enabled successful imaging of neuroendocrine tumors.11 
 In pharmaceutical applications, radioactive metals are used for PET and SPECT imaging. 
The half-life of the radioisotope should be long enough for the synthesis and administration time 




isotope should match that of the final bioactive complex.12 Most often the half-lives of peptides 
and proteins must be increased for accumulation in the target tissue; this goal can be 
accomplished by addition of synthetic polymers such as PEG.13 Although PEG has been used 
successfully in many cases, addition of an inline fusion protein, such as XTEN, simplifies 
production and creates a natural and biodegradable molecule.14,15 XTEN has been fused to 
annexin A5 (AnxA5) to detect phosphatidylserine-exposing cells, which indicate that apoptosis 
is occurring in disease states. AnxA5 has a short half-life of less than 7 min in mice; however, 
inline addition of 288 amino acids of XTEN increases the half-life to 1 h.16 This new technology 
provides the desired pharmacokinetic properties and creates a simplified and well-tolerated 
molecule. 
Currently used contrast agents consist of the chemical conjugation of a chelator that binds 
large lanthanide metals such as gadolinium.17 Gadolinium is often released from the chelator 
upon dilution into the body causing toxicity due to accumulation in the kidney.18 Therefore, a 
tight-binding chelator from a native protein sequence is desired. A successful chelator is the 
calcium-binding sites of the rat a-parvalbumin; these calcium-binding sites were converted to 
Gd3+ binding sites to target tumor tissue with prostate-specific membrane antigen (PSMA).19 
Transition metals are a more biocompatible and safer alternative to lanthanide metal ions; 
however, their use is limited because of the lack of availability of strong chelators. Commonly 
used chelators, such as DOTA, do not bind small transition metals very tightly. For example, 
DOTA was conjugated to an antibody, cetuximab, and complexed with Gd3+ to target and block 
signal transduction of EGFR. Incorporation of Cu2+ rather than Gd3+ created a weak metal 




image due to a high background.20,21 The released copper was observed to accumulate in the 
liver.20,21  
Presented here is the design of a homogenous and site-specific EGFR-targeting imaging 
agent. A novel metal-binding tripeptide, known as the claMP Tag, was created inline with 
epidermal growth factor (EGF), the natural ligand to target EGFR. Inline addition of the claMP 
Tag simplified production of the conjugate compared to chemical conjugation of a synthetic 
moiety to a protein. The claMP Tag consists of the amino acid sequence, Asn-Cys-Cys, and is 
used for transition metal binding with targeting proteins for diagnostic and therapeutic 
applications. Previously, the claMP Tag has been shown to bind tightly to nickel;22,23 described 
here is the first application of using the claMP Tag to complex cobalt. The claMP Tag was 
placed inline with EGF followed by addition of 14, 34, or 57 amino acids of XTEN to create 
EGF-claMP-XTEN fusions with longer half-lives than that of EGF (i.e., longer than  t1/2 of 3–7 
min).24,25 The degradation sites of  EGF-claMP-XTEN fusion proteins were evaluated when 
incubated with serum proteases. The effect of single amino acid mutation to increase proteolytic 
stability was also investigated.  
4.2 MATERIALS AND METHODS  
4.2.1 Genetic Engineering 
Three EGF-claMP-XTEN genes were custom designed to include EGF followed by a 
glycine residue preceding the claMP Tag and varying lengths of XTEN26 (XTEN14, Ser-Ala-








The custom-order genes were purchased from Genescript and user instructions were followed to 
prepare the purchased DNA. To obtain the desired recombinant DNA, primers were used to 
amplify the sequence of interest. Primers contained a region matching the EGF-claMP-XTEN 
sequence shown in bold and a region matching the pET32Xa/LIC vector shown as underlined 
(forward primer, 5’-TCC GGT ATT GAG GGT CGC AAC AGC GAT AGC GAA TGC-3’ 
and reverse primer, 5’-AGA GGA GAG TTA GAG CCT TAG GTG CTG GTG CCT TCT 
TCG GT-3’). The QIAquick PCR Purification Kit (Qiagen) was used to purify the PCR 
reaction, and the product was inserted into the pET-32Xa/LIC vector following the 
manufacturer’s procedure (Novagen). Unexpectedly, the EGF-claMP-XTEN57 construct 
contained two reverse primer annealing sequences on the N-terminus. To purify only the desired 
recombinant DNA sequence, the EGF-claMP-XTEN5 PCR reaction was loaded into a 2% 
agarose gel. The desired product was cut from the gel and placed in an Eppendorf tube. The 
QIAquick Gel Extraction Kit procedure was followed to purify the PCR product, and the 
manufacturer’s procedure was followed in the same way as with the other constructs. Standard 
heat shock procedures were used to transform the LIC reaction into DH5a Escherichia coli (E. 
coli) cell strain. Cells were plated on LB agar plates containing 100 µg/mL ampicillin and 
incubated at 37 °C overnight. Colonies were grown overnight in 5 mL LB with 100 µg/mL 
ampicillin at 250 rpm, 37 °C. Cells were centrifuged at 4000 rpm for 15 min, and the supernatant 
was discarded. A miniprep kit (Qiagen) was used to exploit the DNA, and the sequences were 




4.2.2 Expression of EGF-claMP-XTEN 
Expression and purification of these constructs was highly similar to previously reported 
EGF expression and purification methods.22 Standard heat shock methods were used to transform 
the recombinant DNA into the Origami B (DE3) E. coli strain (Novagen). Colonies were grown 
for approximately 24 h on LB agar plates containing 100 µg/mL ampicillin, 30 µg/mL 
kanamycin, and 12.5 µg/mL tetracycline. Starter cultures were inoculated with individual 
colonies consisting of 50 mL of LB with 100 µg/mL ampicillin for 16 h at 37 °C, 250 rpm. 
Twenty milliliters of starter culture was inoculated into 1 L of LB containing 100 µg/mL 
ampicillin was grown at 37 °C, 250 rpm, until OD reached between 0.6–0.8 (~ 4 h). The protein 
expression was then induced with the addition of 1 mM isopropyl β-D-1-thiogalactopyranoside 
(IPTG). The cells were cultured at 25 °C, 200 rpm, for 16 h and then harvested via centrifugation 
and stored at –80 °C until used.  
4.2.3 Purification of EGF-claMP-XTEN 
Twenty-five milliliters of lysis buffer (50 mM sodium phosphate, 300 mM NaCl, pH 7.4) 
was used to resuspend a 1 L pellet. Three passes through a French press at 21,000 psi were used 
to lyse the cells, followed by centrifugation for 1 h at 21,000 x g and 4 °C. The soluble fraction 
containing the protein was filtered through a 1.2 µm filter followed by a 0.45 µm filter and 
applied to a cobalt-charged HiTrap TALON crude 5 mL column (GE Healthcare Life Sciences) 
equilibrated in lysis buffer. The protein was left on the column at room temperature for 
approximately 1 h to allow metal transfer into the tag. The column was washed with wash buffer 
(50 mM sodium phosphate, 300 mM NaCl, 5 mM imidazole pH 7.4) at 1.25 mL/min for 10 CV. 
The protein was eluted from the column using 25 mL of elution buffer (50 mM sodium 




wash buffer to decrease the imidazole concentration and was concentrated to approximately 4 
mL using an AMICON Ultra 10 kDa MWCO concentrator (Millipore). Eight units of thrombin 
(Fisher Scientific BP254310) per mg protein was incubated with the protein at 16 °C for 9.5 h. 
The protein was diluted to a final volume of 15 mL in wash buffer and re-applied to a 
regenerated Co-TALON column. The flow-through as well as an additional 5 CV of wash buffer 
was collected and diluted 100-fold into 50 mM Tris, 10 mM NaCl pH 7.3. The protein was 
concentrated to 1.8 mL, and calcium chloride at a final concentration of 5 mM was added prior 
to Factor Xa (Novagen, 1.1 mg/mL) being added at a final concentration of 4 µg/mL and 
incubated at room temperature for 16 h. The reaction was applied to a Superdex75 column (GE 
Lifesciences), and the fractions containing the final product were concentrated to approximately 
1 mL.  
4.2.4 Mass Spectrometry 
ESI spectra were acquired on a Waters Synapt G2 hybrid Quadrupole time-of-flight mass 
spectrometer operated in MS mode and acquiring data with the time-of-flight analyzer. The 
instrument was operated in resolution, 22K, mode. The cone voltage was 45eV, and Ar was 
admitted to the collision (trap) cell. Spectra were acquired at the auto pusher frequency covering 
the mass range 50–3000 u. Time to mass calibration was made with NaI cluster ions acquired 
under the same conditions and lock mass corrected with an auxiliary sprayer presenting the 
doubly charged ion, 785.84265, from Glu-fibrinogen peptide.  Lock mass spectra were acquired 
every 30 s.   
Capillary HPLC/MS experiments were performed with a chromatograph that develops 
gradients at 28 µL/min on 0.3 mm ID ´ 5cm C4 RP medium with a Waters Nano Acquity. The 




was held at 1% B for 0.5 min, stepped to 15% by 1 min, and then ramped to 70% by 12 min. 
Column effluent was directed through a 32-gauge needle operated at 2800 V on a standard 
Waters ESI source probe. "Zero" charge spectra for molecular weight information from ESI-
presented charge states were obtained using "Transform" or "MaxEnt I" routines in Masslynx 
software. 
4.2.5 Cell Culture 
The protocol for the cell viability assay was previously described.22 Human epidermoid 
carcinoma cells (A-431 ATCC CRL-1555) and Dulbecco’s Modified Eagle’s Medium (DMEM) 
(ATCC-30-2002) were purchased from ATCC. A-431 cells were cultured in DMEM 
supplemented with 10% fetal bovine serum (FBS), 1% penicillin, and 1% streptomycin. The 
culture method recommended by ATCC was followed and the cells were grown in an incubator 
at 37 °C and 5% CO2. 
4.2.6 EGF Cell Viability Assay  
After the A-431 cells reached confluency, they were passaged, and plated at a density of 
10,000 cells per well were plated in a 96-well clear-bottom black plate. The cells were placed in 
the incubator overnight, and the following day the medium was replaced with medium 
containing the treatments and controls.  The treatments were diluted into the medium at the 
appropriate concentrations and added to the wells, after which they were placed in the incubator 
for 72 h. Resazurin was added to A-431 cultures at a final concentration of 0.09 mg/mL and was 
incubated for 3 h before measuring the fluorescence (560 nm excitation, 590 nm emission) using 




4.2.7 Stability Samples 
Immediately after purification, stability analysis of the protein was started. Each day 20 
µL samples of a 0.1 mM stock solution of protein were mixed with 20 µL of non-reducing 
lamelli buffer and incubated at 90 °C for 10 min to create the samples for SDS-PAGE. Samples 
were left at room temperature or 4 °C and stability was analyzed at both temperatures. 
4.2.8 Enzymatic Incubation 
Factor Xa or thrombin were added to a 0.1 mM protein sample to a final concentration of 
11 µg/mL Factor Xa (Novagen, 1.1 mg/mL) or 50 U/mL thrombin (Fisher Scientific BP254310). 
Incubation occurred at room temperature and samples were taken at time points 0, 10, 12, 14, 16, 
18, 20, 22, and 36 h. At the specified time points, 25 µL of the protein sample was mixed with 25 
µL reducing lamelli buffer and incubated at 90 °C for 10 min to create samples for SDS-PAGE.  
4.2.9 SDS-PAGE 
SDS-PAGE consisting of 4% (v/v) stacking and 20% (v/v) resolving gels was used to 
visualize the stability and proteolysis over time. A prestained molecular weight ladder (Biorad 
#161-0374) was used as a reference, and the gels were stained with coomassie. 
4.2.10 Densitometry Analysis 
Protein bands on the SDS-PAGE gels were quantified using the Odyssey CLx Imaging 
System (Li-cor). Gels were imaged and quantified using the fluorescence emission of coomassie 
at 700 nm (excitation ~ 650 nm).27 
4.3 RESULTS  
4.3.1 Design of EGF-claMP-XTEN Constructs  
 Three variants of a claMP-Tagged EGFR-targeting molecule were designed as inline 




factor (EGF), which is the natural ligand of epidermal growth factor receptor (EGFR), and was 
ideal to use as a target to EGFR (+) tumor cells. EGF was genetically engineered inline with the 
claMP Tag followed by either 14, 34, or 57 amino acids of XTEN (Figure 4.1). Previously, a 
claMP-Tagged EGF molecule was expressed and purified as a fusion protein;22 here the fusion 
protein was modified by the addition of XTEN (Supplementary Figure 4.1 and 4.2). Prior 
purification efforts have utilized nickel-immobilized metal affinity chromatography (Ni-IMAC) 
for both purification through the His6 tag and incorporation of metal into the claMP Tag. 
Primarily, previous efforts to characterize the claMP Tag have been accomplished using nickel 
because of the unique properties of the Ni-claMP Tag, such as tight metal-binding and rich 
spectroscopic features. Described here is the first exploration of cobalt complexed to the claMP 
Tag for SPECT and PET imaging. 
	
Figure 4.1 Cartoon of EGF-claMP-XTEN fusion constructs. (A) The fusion partner of each construct consists of 
Thioredoxin, His Tag and S-Tag followed by EGF and the claMP Tag (Asn-Cys-Cys) and either 14, 34 or 57 amino 
acids of XTEN. Enzymatic recognition sequences are built into the fusion protein to enable removal of the fusion 






4.3.2 Investigation of the Co-claMP Tag Complex 
While the nickel-bound claMP Tag has been extensively studied and is known to form an 
extraordinarily stable complex,28 the Co-claMP Tag has yet to be investigated. Cobalt was 
compared to nickel to understand relative differences between the two metal-bound claMP Tag 
complexes. Cobalt was introduced into the claMP Tag in a manner similar to that previously 
completed with nickel. The claMP-Tagged conjugates were placed on a 5-mL cobalt-charged 
TALON column to permit exchange of cobalt into the claMP Tag. The expectation was that 
cobalt and nickel would behave very similarly as both have a +2-charge and are located adjacent 
on the periodic table. Initial comparisons between cobalt and nickel consisted of investigating the 
EGF-claMP-XTEN34 fusion protein purified by either nickel or cobalt affinity chromatography. 
Absorption spectroscopy was used to determine metal uptake by the claMP Tag (Figure 4.2). 
Metal binding occurred in both nickel- and cobalt-purified samples and was confirmed by a 
visual color change from a clear protein solution to a rusty orange/brown color upon exposure to 
metal (Supplementary Figure 4.3). Spectroscopic features have yet to be characterized for the 
cobalt-claMP Tag. To determine the extent of cobalt binding to the claMP Tag, the Co-claMP 
Tagged protein sample was placed over a nickelated column. Unoccupied claMP Tag sites will 
readily incorporate nickel, allowing quantification of cobalt occupation of the claMP Tag. 
Specifically, the Ni-claMP Tag can be quantified by a peak in the visible region at approximately 
410 nm, and the 280/410 nm ratio aligns with complete occupancy (Table 4.1). Spectroscopic 
features at 410 nm were observed for both nickel- and cobalt-purified samples (Figure 4.2). The 
ratio of the 280 nm to 410 nm peak was unchanged when placed over the nickelated column, 
indicating that cobalt fully occupies the claMP Tag (Table 4.1). A peak in the visible region of 




Tag. Comparing the Co-claMP Tag intensity at 410 nm to the Ni-claMP Tag shows that the 
relative molar absorptivity is approximately three-fourths of that of the Ni-claMP Tag (Table 
4.1).  
Table 4.1 Comparison of Nickel and Cobalt Binding to the claMP Tag 
Purification Method Ratio of 280/410 
Relative Molar 
Absorptivitya 
Ni purified 39 ± 3 1.00 ± 0.09 
Co purified 52 ± 4 0.75 ± 0.05 
Co followed by Ni 53 ± 4 0.73 ± 0.06 
aMolar absorptivity at 410 nm compared to the nickel purified sample. 
 
Non-reducing SDS-PAGE and mass spectrometry indicate covalent disulfide 
dimerization occurring in the EGF-claMP-XTEN constructs. Dimerization was confirmed by 
mass spectrometry (monomer 11769.59 Da and dimer 23539.41 Da) (Supplementary Figure 4.4). 
Reducing SDS-PAGE eliminated higher molecular weight species (data not shown), indicating 
that covalent disulfide bonds are formed. Quantification of the higher molecular weight, dimeric, 
and monomeric species was completed using non-reducing SDS-PAGE and densitometry 
	
Figure 4.2 Comparison of nickel and cobalt claMP Tag complexes within the EGF-claMP-XTEN34 fusion 
protein. Absorption spectrum of nickel-bound and cobalt-bound claMP Tag and identification of similar peaks at 





analysis (Figure 4.3). Dissociation of higher molecular weights species to monomeric species 
occurs after the concentration and dilution step; at higher temperature, dissociation occurs more 
rapidly (Figure 4.3). EGF-claMP-XTEN constructs contain eight Cys residues, six Cys residues 
within EGF forming three disulfide bonds, and two Cys residues within the claMP Tag, any of 
which could be responsible for dimerization. Removal of the claMP Tag Cys residues was 
completed using site-directed mutagenesis of the two Cys residues to Ala and, upon purification, 
dimerization no longer occurred. Therefore, dimerization is through the claMP Tag Cys residues 
and not the three disulfide bonds within EGF.  
Fragmentation of the protein over time was also observed and, at 4 °C, less than 10% 
fragmentation occurred, while at room temperature almost 50% of the protein is fragmented after 
three days. To understand this further, a control protein consisting of only EGF was purified 
using the cobalt purification method. EGF remains monomeric and stable for at least one week 
(longest time examined) and non-reducing SDS-PAGE lacks dimerization. A fragment of EGF 
consisting of EGF without the C-terminal Arg53 residue was identified by mass spectrometry. 
	
Figure 4.3 Quantification of higher molecular weight, dimer, monomer and fragment species of EGF-
claMP-XTEN34. Stability was analyzed at (A) 4 °C and (B) room temperature (approximately 25 °C). 
Quantification was completed using a densitometry analysis of SDS-PAGE. Error bars represents standard 





Cleavage at this site was also observed with EGF-Ni-claMP constructs, but only a small amount 
accumulated over 2 months, with the initial identification after 8 weeks.29 Purification using 
cobalt may impact the stability of EGF, causing more rapid cleavage between Leu52 and Arg53. 
4.3.3 Addition of XTEN Does Not Impact EGF Yield or Function 
 Addition of XTEN to the C-terminus of EGF is expected to have little to no impact on the 
structure or function of EGF-claMP. Expression and purification of the XTEN constructs 
resulted in similar yields at each purification step for both nickel and cobalt purifications (Table 
4.2).  
Table 4.2 Addition of XTEN Does Not Impact Yield of EGF-claMP-XTEN Constructs 
Construct Post IMAC (mg)a 
Post Thrombin 
Cleavage (mg)a 




Ni-purified EGF 30 ± 10 17 ± 1 4.2 ± 0.9 16 ± 5 
Co-purified EGF 13.3 10.2 2.5 18.8 
Ni-EGF-claMP-XTEN14 40 ± 10 16 ± 5 4.1 ± 0.9 11 ± 1 
Co-EGF-claMP-XTEN14 24 ± 9 14 ± 6 2.5 ± 0.6 11 ± 2 
Co-EGF-claMP-XTEN34 30 ± 10 14 ± 6 1.2 ± 0.4 5 ± 1 
Co-EGF-claMP-XTEN57 19 ± 6 9 ± 1 1.5 ± 0.4 9 ± 4 
aReported as mass equivalents of EGF-claMP-XTEN construct and were calculated by taking the final EGF-claMP 
XTEN mass as a fraction of the fusion protein. bYield was calculated by taking the post Factor Xa cleavage mass as 
a fraction of the initial post IMAC mass. 
 Conjugation of a fusion protein or polymer to a targeting protein can interfere with the 
ability of the molecule to target the receptor by blocking receptor binding. The functionality of 
the EGF-claMP-XTEN was examined using an A431 epidermoid carcinoma cell line, which 
overexpresses EGFR on the surface of the cells (Figure 4.4). Addition of EGF to the A431 cell 
line causes the previously established, albeit unexpected result of cell death.30 The control 
protein, EGF, was compared to the Co-EGF-claMP-XTEN constructs. Cell viability decreased at 




nM indicating that addition of Co-claMP-XTEN does not impact the functionality of EGF 
(Figure 4.4).  
4.3.4 Investigation of Proteolytic Stability of EGF-claMP-XTEN 
EGF-claMP-XTEN constructs were exposed to two serum proteases, thrombin and 
Factor Xa, and their proteolytic susceptibility was examined. Degradation of the intact molecule 
into smaller molecular weight fragments was visualized using SDS-PAGE (Supplementary 
Figure 4.5) and quantified with a densitometry analysis. The decrease in the intensity of the 
intact protein was quantified and the constructs were compared at the 0, 12, 22, and 36 h time 
points (Figure 4.5). The three constructs behaved in a highly similarly manner when cleaved with 
Factor Xa or thrombin. After 36 h, thrombin cleaved 73.9% of EGF-claMP-XTEN14, 63.5% of 
EGF-claMP-XTEN34, and 71.1% of EGF-claMP-XTEN57, while Factor Xa cleaved 33.3% 
EGF-claMP-XTEN14, 48.3% of EGF-claMP-XTEN34, and 42.5% of EGF-claMP-XTEN57.  
	
Figure 4.4 Inline addition of XTEN residues on the C-terminus of EGF has no influence on the function 






Figure 4.5 Comparison of the enzymatic cleavage of EGF-claMP-XTEN14 (XTEN14), EGF-claMP-XTEN34 
(XTEN34), and EGF-claMP-XTEN57 (XTEN57) constructs by (a) thrombin and (b) Factor Xa at 0, 12, 22, 
and 36 h incubation. Error bars represent standard deviation between two separate protein purifications.	
Identification of cleavage sites within EGF-claMP-XTEN34 and EGF-claMP-XTEN57 
was completed using mass spectrometry (Table 4.3, Figure 4.6). Cleavage sites within EGF-
claMP-XTEN34 and EGF-claMP-XTEN57 were highly similar, and multiple cleavage sites 
within XTEN were identified. Both constructs showed cleavage between Leu52 and Arg53, the 
terminal amino acid of EGF. Proteolysis prior to Arg53 was observed by Factor Xa, but not by 
thrombin within the EGF-claMP-XTEN34 construct. Both thrombin and Factor Xa cleaved 
EGF-claMP-XTEN57 prior to Arg53, indicating that it is a site of proteolysis by both thrombin 
and Factor Xa; however, thrombin does not prefer this site within EGF-claMP-XTEN34.  
An amino acid mutation of Arg53 to Ala (Arg53Ala, R53A) was completed within EGF-
claMP-XTEN34. Arg53Ala showed vast improvement in the proteolytic stability of EGF-
claMP-XTEN34 with 17.5% of the protein cleaved compared to 48.3% cleaved without the 
mutation. Proteolytic stability was improved 2.8-fold by a single amino acid mutation with 
respect to Factor Xa (Figure 4.7a). Thrombin was not influenced by the amino acid mutation, as 




4.7b). This is consistent with the mass spectrometry analysis that indicated that Leu52-Arg53 is 
not a site of proteolysis for thrombin within EGF-claMP-XTEN34, and that proteolysis is 
occurring at other sites, specifically within XTEN. Mass spectrometry was used to identify major 
cleavage sites within EGF-claMP-XTEN34 Arg53Ala (Table 4.3, Figure 4.6), most prominently 
within XTEN.  
Table 4.3 Fragmentation of EGF-claMP-XTEN Constructs Identified by Mass Spectrometry 







Occursa Thrombin Factor Xa 
F1 EGF-claMP-XTEN[1-46] 10642.5 10635.4 ± 0.17 x x ­ 
F2 EGF-claMP-XTEN[1-10] 7311.2 7302.6 ± 2.7 x x ü 
F3 EGF-claMP-XTEN[1-3] 6828.7 6820.03 ± 0.12 x x ý, ü,­ 
F4 EGF[1-52] 6065.8 6059.27 ± 0.01  x ý, ­ 
F5 XTEN[4-31] 2969.9 2969.2 x x ý, ü 
F6 XTEN[18-34] 1613.6 1615.3 x x ü 
F7 XTEN[23-34] 1138.1 1137.7 x x ý 





Figure 4.6 Cartoon of EGF-claMP-XTEN34 and EGF-claMP-XTEN57 with labeled cleavage sites identified by 
mass spectrometry. Table 4.3 describes the fragments identified by mass spectrometry that are referred to in this 
figure. Proteolysis occurred at site indicated by the bracket within the protein sequence to yield the fragments within 
each color-coded bracket. One site was found only in EGF-claMP-XTEN57 and is represented by a highlighted 







Figure 4.7 Enzymatic cleavage of EGF-claMP-XTEN34 Arg53Ala incubated with either (a) thrombin or (b) 
Factor Xa. Enzymatic reactions were completed at room temperature and samples were taken at 0, 12, 22, and 36 h.	
4.4 DISCUSSION 
 A candidate molecule for molecular imaging applications was designed; it consisted of 
three functional segments: (1) the targeting protein: epidermal growth factor (EGF), (2) a metal-
binding entity: the claMP Tag, and (3) a hydrophilic polymer of amino acids used to extend the 
half-life of recombinant proteins: XTEN. Inline addition of these molecules creates a targeted 
molecular imaging agent with a tunable half-life, and the synchronization of these three entities 
was characterized to understand the stability of the molecule. Here, cobalt was explored within 
the claMP Tag as a safer metal for imaging than the currently used lanthanide ions. The most 
commonly used contrast agents are gadolinium-based, which have proven to be toxic to patients 
with renal impairment. Further studies have shown retention of Gd3+ in critical tissues such as 
the brain.31,32 Cobalt was chosen to study because incorporation of cobalt into chelators such as 
DOTA has been successful at probing tumors; for example, a 57Co-labeled octreotide analog was 




Tag resulted in determination of complete occupy of cobalt in the claMP Tag (Figure 4.2, Table 
4.1). Further characterization identified higher molecular weight covalently linked species 
(Figure 4.3) that are formed through the Cys residues within the claMP Tag. This was confirmed 
by lack of dimerization upon mutation of the claMP Tag Cys residues to Ala residues. 
Dimerization occurs through the claMP Tag and is most likely caused by partial loss of cobalt 
from the claMP Tag over time.  
 Rather than chemical conjugation of a synthetic polymer such as PEG to EGF-claMP, 
XTEN was genetically engineered to the C-terminus of the protein sequence. Three different 
lengths of XTEN were examined here as an initial analysis of the effect of XTEN on the 
structure and function of both EGF and the claMP Tag. The number of XTEN amino acids can 
be easily manipulated to create the desired half-life of the molecule and 14, 34, and 57 amino 
acids were chosen as initial lengths. XTEN did not affect the expression or purification of EGF-
claMP, and did not inhibit receptor binding (Table 4.2, Figure 4.4). Addition of more amino 
acids of XTEN may decrease interaction of EGF with the receptor, and this must be considered 
when designing molecules with longer XTEN polymers. A decrease in receptor binding is not 
necessarily undesirable; for example, Somavaratan (VRS-317, Versartis) utilizes XTEN on both 
the N- and C-termini of recombinant human growth hormone (rhGh) to both decrease renal 
clearance and reduce receptor binding affinity to delay receptor-mediated clearance mechanisms. 
Somavaratan exhibits a 30–60-fold increase in half-life compared to rhGh, allowing once 
monthly dosing.34,35 The ability to easily tune the length of XTEN was a desirable feature that 
warranted investigation of the use of XTEN in this system.  
 Finally, the proteolytic stability of the three molecules was analyzed and compared to 




of the intact protein and create a more stable and effective molecule. Enzymatic incubation 
studies incubated that proteolysis by Factor Xa and thrombin occurred at multiple sites within 
XTEN. Although proteolysis occurs within XTEN, this is not a main concern as XTEN is known 
to be biodegradable and, over time, will be degraded by proteolysis. The main area of concern is 
proteolysis at the C-terminus of EGF, ultimately separating the targeting protein from the 
imaging modality and rendering the imaging agent ineffective. The primary site of concern is 
cleavage between Leu52 and Arg53, where the Co-claMP Tag is separated from EGF. Previous 
stability studies of EGF-Ni-claMP indicated cleavage at this same site and hypothesized that this 
was due to an enzymatic contaminant or metal-catalyzed chemical reaction.29 Mutation of Arg53 
to Ala inhibited Factor Xa cleavage, although thrombin cleavage still persisted (Figure 4.6). 
Thrombin and Factor Xa are known to have broad specificity and to cleave at multiple sites. 
Both thrombin and Factor Xa cleave after Arg residues within the recognition sequences Ile-Glu-
Gly-Arg and Leu-Val-Pro-Arg-Gly, respectively.36,37 Proteolysis within XTEN was the major 
source of proteolysis within both EGF-claMP-XTEN34 and EGF-claMP-XTEN57. Cleavage 
within XTEN was of less concern, as XTEN is known to be biodegradable. Three of the seven 
fragments within XTEN were caused by cleavage after Gly residues and, since Gly is a flexible 
residue, this is not surprising. The half-life will decrease as XTEN is degraded, and very similar 
sites of proteolysis were identified in EGF-claMP-XTEN34 and EGF-claMP-XTEN57. 
Analyzing proteolysis by two serum proteases, Factor Xa and thrombin, is a place to begin the 
analysis of degradation. Complete analysis of degradation in serum would yield further 
fragmentation and amino acid mutations that could potentially be used to create a more stable 





 Here, an improved molecular probe was investigated by using the claMP Tag inline with 
a targeting protein to accomplish the targeted delivery of transition metals. This molecule was 
designed to have site-specific engineering of metal binding to the protein and formed a 
homogeneous molecule that could be easily produced in E. coli. A relevant SPECT and PET 
metal was investigated in this system and cobalt was determined to fully occupy the claMP Tag.  
The XTEN fusion partner can be added to the protein and can be tuned to increase the size and 
ultimately the half-life of the molecule. XTEN does not have an impact on functionality with as 
large an addition as 57 amino acids to the C-terminus. The initial analysis of EGF-claMP-XTEN 
constructs proved promising, and further research is warranted to investigate the ability of this 
molecule to probe EGFR (+) tumor cells.  
4.6 SUPPLEMENTARY FIGURES 
 
Supplementary Figure 4.1 Expression of EGF-claMP-XTEN14 (lanes 2 and 3), EGF-claMP-XTEN34 (lanes 4 
and 5) and EGF-claMP-XTEN57 (lanes 7 and 8) represented by Coomassie-stained SDS-PAGE. Lane 1 and 6 







Supplementary Figure 4.2 Purification of EGF-claMP-XTEN34. Molecular weight ladder (lane 1), soluble 
fraction of the cell lysate (lane 2), flow through of application of the cell lysate to Co-TALON (lane 3), flow through 
of the 5 mM imidazole wash buffer (lane 4), elution of fusion protein (lane 5), after incubation for 9.5 h with 
thrombin (lane 6), separation of thioredoxin-tag (lane 7), separation of thrombin-cleaved protein (lane 8), after 
incubation for 16 h with Factor Xa (lane 9), after SEC separation of final EGF-claMP-XTEN34 (lane 10). EGF-
claMP-XTEN34 appears at a higher mass than expected because of XTEN, which increases the hydrodynamic 












Supplementary Figure 4.4 Mass spectrometry identifies the presence of the monomer and dimer of EGF-
claMP-XTEN57. Monomer average theoretical mass is 11777.6 Da and dimer average theoretical mass is 23537.2 
Da. 
	
Supplementary Figure 4.5 Example SDS-PAGE of EGF-claMP-XTEN57 treated with (A) Thrombin or (B) 
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CHAPTER 5. CONCLUSIONS AND FUTURE WORK 
	
5.1 MAJOR CONCLUSIONS  
  Reported in this work is the first exploration of the influence of the claMP Tag on 
proteolysis. The claMP Tag is a novel metal-binding tripeptide that can be placed inline with a 
targeting protein to specifically deliver transition metals to cells of interest. Applications of the 
claMP Tag are being explored in the areas of therapy and diagnosis of cancer. One application 
consisted of determining the implications of the claMP Tag inline with a matrix 
metalloproteinase (MMP). MMP-8 is known to degrade extracellular matrix proteins and its 
activity is often dysregulated in disease states. Investigation of MMP-8 led to determination of a 
method to express and purify large quantities of soluble and active MMP-8. Ultimately, the 
claMP Tag exhibited no structural or functional implications on MMP-8. The ability to place the 
claMP Tag within a protease with a metal-binding active site presents opportunities to use the 
claMP Tag to modulate metalloenzymatic activity. 
 An alternative application was investigating the ability of the claMP Tag to inhibit 
adjacent proteolysis. When designing biologics, one major limitation is rapid degradation of the 
biologic by proteases upon administration. Biologics are most commonly delivered by injection 
directly to the systemic circulation in an effort to overcome absorption and enzymatic barriers at 
alternative sites of administration. However, the systemic circulation is home to active proteases 
as well. Proteolytic cleavage adjacent to the claMP Tag was investigated with respect to a 
relevant serum protease that is most likely encountered upon administration. A proof-of-concept 
study was designed to probe the ability of the claMP Tag to inhibit adjacent proteolysis. 




was able to inhibit Factor Xa 3-fold compared to the control. In addition to providing site-
specific, inline addition of transition metals, the claMP Tag is able to resist adjacent proteolysis.  
 Additionally, the use of the claMP Tag as a complex to enable molecular imaging was of 
interest. This work describes the first attempts to bind cobalt to the claMP Tag. Complete 
occupancy upon exposure to cobalt was confirmed by visual inspection and quantification of 
spectroscopic features. XTEN was also placed inline with the claMP Tag to improve the half-life 
of the small protein EGF. XTEN did not impact the structure or function of EGF, and was 
determined to be a desirable way to easily tune the size of the molecule to achieve the desired 
half-life. Accessible sites of proteolysis were identified, most of which were within the XTEN 
sequence. Cleavage between Leu52 and Arg53 was particularly important as these are the 
terminal residues of EGF and cleavage separates the targeting protein from the metal-bound 
claMP Tag and XTEN. An amino acid mutation improved stability and decreased Factor Xa 
proteolysis by 2.8-fold.  
5.2 FUTURE DIRECTIONS 
5.2.1 Investigation of the claMP Tag’s Ability to Regulate Metalloproteinase Activity  
 The compatibility of the claMP Tag placed inline with a matrix metalloproteinase was 
investigated. The claMP Tag followed by an eight-amino acid linker sequence was placed on the 
N-terminus of MMP-8. The goal was for the claMP Tag to have enough flexibility at the end of 
the linker sequence to reach in and bind the Zn2+ ion in the active site of MMP-8. It has been 
previously reported that the claMP Tag binds the Zn2+ active site within MMP-8, inhibiting its 
activity.1 Initial structural analysis of the MMP-8 fusion protein has been completed previously. 
NMR was used to probe the ability of the metal abstraction peptide (MAP) (Asn-Cys-Cys) to 




MMP-8, most likely at the Zn2+ active site. Further studies using alternative protein-labelling 
techniques are necessary to elucidate these structural interactions.  
 The linker sequence designed in our initial studies was not long enough to reach the 
active site of MMP-8 as nickel was incorporated into the claMP Tag. Upon purification, it was 
revealed that the claMP Tag was not bound to the Zn2+ active site. An engineered enzymatic 
recognition sequence was placed between the linker and MMP-8 to allow release of the claMP 
Tag when it encountered Factor Xa. This prodrug approach allows release of the claMP Tag 
from the enzyme once it reaches a particular enzymatic environment. The ability to control the 
activity of MMP-8 would be a great advantage for diseases where MMP-8 activity is 
dysregulated.  
5.2.2 Investigation of the Co-claMP Tag Complex 
 The Ni-claMP Tag complex has been extensively characterized, and many applications 
using the Ni-claMP Tag as a proof-of-concept have been completed because of the ideal qualities 
of this complex, such as rich spectroscopic features and tight metal-binding.2,3 Initial studies with 
solely the metal abstraction peptide (MAP) (Asn-Cys-Cys) bound to nickel were completed.4 
The claMP Tag has been shown to bind nickel with 100% occupancy when placed within a small 
protein and to remain stable for months at a time.5,6 Nickel lacks molecular imaging capabilities; 
thus applying SPECT-active metals such as cobalt will provide insight into the use of the claMP 
Tag as a molecular probe. Because cobalt is adjacent to nickel on the periodic table and also 
carries a +2 charge, incorporation of cobalt was hypothesized to be fairly similar to that of 
nickel. Thus, a claMP-Tagged protein was exposed to cobalt affinity chromatography to 
successfully occupy the claMP Tag with cobalt. Initial studies determined full occupancy of the 




nm, was observed for both nickel and cobalt, albeit cobalt with approximately three-fourths the 
intensity of nickel (Table 4.2). To fully characterize the Co-claMP Tag complex, studies using 
the Asn-Cys-Cys peptide and cobalt binding can provide insight into geometry and strength of 
metal-binding. Stability analysis with respect to other chelators such as EDTA and pH titrations 
to understand the pH range of metal-binding can be completed to fully characterize this complex. 
Additional analytical techniques such as ICP-MS can be used to quantify metal within the claMP 
Tag. 
 Dimerization and higher molecular weight species formed upon purification of these 
constructs and were determined to occur through covalent disulfide bonds. EGF without claMP-
XTEN is stable, and previous experiments with EGF-Ni-claMP Tag proved that it is stable and 
monomeric as well.5 Cobalt purification and loss of metal from the claMP Tag over time most 
likely causes dimerization to occur in these samples. Further analysis of the stability of the EGF-
Co-claMP Tag constructs will identify ways to prevent dimerization. Fragmentation also 
occurred within these fusion proteins, primarily between Leu52 and Arg53 prior to the addition 
of enzymes. Fragmentation could be due to a metal-catalyzed cleavage event or the presence of 
an enzymatic contaminant. Further investigation of the Co-claMP Tag will elucidate many of the 
instabilities encountered with the EGF-claMP-XTEN constructs.  
5.2.3 In vivo Studies of a claMP-Tagged Molecular Probe 
 The overall goal of investigating the stability of the claMP-Tagged EGFR targeting 
molecules is to create an improved imaging agent. Receptor recognition and binding of the EGF-
claMP-XTEN constructs was confirmed using an epidermoid carcinoma cell line that 
overexpresses epidermal growth factor receptor (EGFR) on the surface of the cell. Often when 




to a decrease in receptor binding. Some pharmaceuticals take advantage of this prospect and add 
polymers to both the N- and C-termini of the targeting protein to reduce receptor-mediated 
clearance and further increase the half-life. For example, Somavaratan (Versartis) consists of an 
N- and C-terminal XTEN fusion to accomplish half-life enhancement.7,8 The addition of XTEN 
to EGF did not impact the function of EGF, but does increase its size and thus its circulating 
half-life. More XTEN amino acids can be added to the N- or C-terminus to increase the half-life 
further to achieve the desired pharmacokinetics. 
 Here, the design and characterization of a preliminary imaging molecule was completed 
with the over-arching goal of creating a biologically relevant claMP-Tagged molecular probe. 
The benchtop application investigated here, used cobalt scavenged from a 5-mL TALON column 
charged with CoCl2. For SPECT and PET imaging, radioactive metal ions are required. The 
EGF-claMP-XTEN constructs would need to be produced in the empty or apo claMP Tag form 
and then prior to administration, loaded with the radioactive metal. Different cobalt isotopes 
could be used for different purposes. For example, 57Co or 58mCo can be used for imaging or 
therapeutic purposes, respectively.9 The molecule would need to be stable in the body only hours 
before degradation occurred, meaning that some of the instabilities seen over days become 
irrelevant. Dosing this imaging agent to animals with head and neck tumors that overexpress 
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